

# Basal Cell Skin Cancer, Version 2.2024

Chrysalyne D. Schmults, MD, MS<sup>1,\*</sup>; Rachel Blitzblau, MD, PhD<sup>2,\*</sup>; Sumaira Z. Aasi, MD<sup>3</sup>; Murad Alam, MD, MBA, MSCI<sup>4</sup>; Arya Amini, MD<sup>5</sup>; Kristin Bibee, MD, PhD<sup>6</sup>; Jeremy Bordeaux, MD, MPH<sup>7</sup>; Pei-Ling Chen, MD, PhD<sup>8</sup>; Carlo M. Contreras, MD<sup>9</sup>; Dominick DiMaio, MD<sup>10</sup>; Jessica M. Donigan, MD<sup>11</sup>; Jeffrey M. Farma, MD<sup>12</sup>; Karthik Ghosh, MD<sup>13</sup>; Kelly Harms, MD, PhD<sup>14</sup>; Alan L. Ho, MD, PhD<sup>15</sup>; John Nicholas Lukens, MD<sup>16</sup>; Lawrence Mark, MD, PhD<sup>17</sup>; Theresa Medina, MD<sup>18</sup>; Kishwer S. Nehal, MD<sup>15</sup>; Paul Nghiem, MD, PhD<sup>19</sup>; Kelly Olino, MD<sup>20</sup>; Soo Park, MD<sup>21</sup>; Tejesh Patel, MD<sup>22</sup>; Igor Puzanov, MD, MSCI<sup>23</sup>; Jason Rich, MD<sup>24</sup>; Aleksandar Sekulic, MD, PhD<sup>13</sup>; Ashok R. Shaha, MD<sup>15</sup>; Divya Srivastava, MD<sup>25</sup>; Valencia Thomas, MD<sup>26</sup>; Courtney Tomblinson, MD<sup>27</sup>; Puja Venkat, MD<sup>28</sup>; Yaohui Gloria Xu, MD, PhD<sup>29</sup>; Siegrid Yu, MD<sup>30</sup>; Mehran Yusuf, MD<sup>31</sup>; Beth McCullough, RN, CMSRN<sup>32</sup>; and Sara Espinosa, PhD<sup>32</sup>

## ABSTRACT

Basal cell carcinoma (BCC) is the most common form of skin cancer in the United States. Due to the high frequency, BCC occurrences are not typically recorded, and annual rates of incidence can only be estimated. Current estimated rates are 2 million Americans affected annually, and this continues to rise. Exposure to radiation, from either sunlight or previous medical therapy, is a key player in BCC development. BCC is not as aggressive as other skin cancers because it is less likely to metastasize. However, surgery and radiation are prevalent treatment options, therefore disfigurement and limitation of function are significant considerations. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) outline an updated risk stratification and treatment options available for BCC.

*J Natl Compr Canc Netw* 2023;21(11):1181–1203  
doi:10.6004/jnccn.2023.0056

## NCCN CATEGORIES OF EVIDENCE AND CONSENSUS

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

**All recommendations are category 2A unless otherwise noted.**

**Clinical trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

## PLEASE NOTE

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>) makes no representations or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

**The complete NCCN Guidelines for Basal Cell Skin Cancer are not printed in this issue of JNCCN but can be accessed online at [NCCN.org](https://www.nccn.org).**

© 2023, National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>). All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

## Disclosures for the NCCN Basal Cell Skin Cancer Panel


At the beginning of each NCCN Guidelines Panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Basal Cell Skin Cancer Panel members can be found on page 1203. (The most recent version of these guidelines and accompanying disclosures are available at [NCCN.org](https://www.nccn.org).)

**The complete and most recent version of these guidelines is available free of charge at [NCCN.org](https://www.nccn.org).**

<sup>1</sup>Dana-Farber/Brigham and Women's Cancer Center | Mass General Cancer Center; <sup>2</sup>Duke Cancer Institute; <sup>3</sup>Stanford Cancer Institute; <sup>4</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University; <sup>5</sup>City of Hope National Medical Center; <sup>6</sup>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; <sup>7</sup>Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; <sup>8</sup>Moffitt Cancer Center; <sup>9</sup>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; <sup>10</sup>Fred & Pamela Buffett Cancer Center; <sup>11</sup>Huntsman Cancer Institute at the University of Utah; <sup>12</sup>Fox Chase Cancer Center; <sup>13</sup>Mayo Clinic Comprehensive Cancer Center; <sup>14</sup>University of Michigan Rogel Cancer Center; <sup>15</sup>Memorial Sloan Kettering Cancer Center; <sup>16</sup>Abramson Cancer Center at the University of Pennsylvania; <sup>17</sup>Indiana University Melvin and Bren Simon Comprehensive Cancer Center; <sup>18</sup>University of Colorado Cancer Center; <sup>19</sup>Fred Hutchinson Cancer Center; <sup>20</sup>Yale Cancer Center/Smilow Cancer Hospital; <sup>21</sup>UC San Diego Moores Cancer Center; <sup>22</sup>University of Tennessee Health Science Center; <sup>23</sup>Roswell Park Comprehensive Cancer Center; <sup>24</sup>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; <sup>25</sup>UT Southwestern Simmons Comprehensive Cancer Center; <sup>26</sup>The University of Texas MD Anderson Cancer Center; <sup>27</sup>Vanderbilt-Ingram Cancer Center; <sup>28</sup>UCLA Jonsson Comprehensive Cancer Center; <sup>29</sup>University of Wisconsin Carbone Cancer Center; <sup>30</sup>UCSF Helen Diller Family Comprehensive Cancer Center; <sup>31</sup>O'Neal Comprehensive Cancer Center at UAB; and <sup>32</sup>National Comprehensive Cancer Network.

\*Discussion Writing Committee Member.



<sup>a</sup> Principles of Pathology (BCC-A).

<sup>b</sup> Risk Factors for Recurrence (BCC-B).

<sup>c</sup> Morgan FC, et al. J Am Acad Dermatol 2021;85:582-587.

<sup>d</sup> Extensive disease includes deep involvement such as bone, named nerves, and deep soft tissue. If disease of named nerve(s) is suspected, MRI with and without contrast is preferred. If bone disease is suspected, CT with contrast is preferred unless contraindicated.

<sup>e</sup> Any high-risk factor places the patient in the high-risk category.

<sup>f</sup> For rare cases that present with regional or distant metastatic disease at diagnosis, treat per nodal or metastatic pathways on BCC-4.

<sup>g</sup> Imaging modality and targeted area should be at the discretion of the treating team based on the suspected extent of disease (ie, local, regional, metastatic). Histologic confirmation is sufficient to diagnose local recurrence, but MRI with and without contrast can be considered to assess extent of local disease. For nodal or distant metastasis, histologic analysis and/or CT imaging can be used for confirmation and to gauge extent of disease.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-1

## Overview

Basal cell carcinoma (BCC) is the most common cancer in the United States. It is estimated that BCCs occur in 2 million Americans annually, exceeding the incidence of all other cancers combined.<sup>1-3</sup> BCCs are at least 2 times more common than squamous cell carcinomas (SCCs), the second most common type of skin cancer.<sup>1-6</sup> Furthermore, the incidence of this common malignancy is rising rapidly.<sup>1,3,6,7</sup> Compared with SCC, BCCs are much less likely to metastasize, with a metastatic rate of <0.1%, and thus generally have a good prognosis.<sup>8-10</sup> Although rarely metastatic, BCC can produce substantial local destruction along with disfigurement and may involve extensive areas of soft tissue, cartilage, and bone.

A number of risk factors are associated with the development of BCC. The most recognized environmental carcinogen is sunlight. Evidence reveals that the relationship between sun exposure and BCC is complex and depends on the timing, pattern, and amount of ultraviolet radiation.<sup>11-15</sup> Fair skin, red or blond hair, and light eye color are associated with BCC as independent risk factors due to greater susceptibility to ultraviolet damage.<sup>13,15-22</sup> BCC risk is increased by both ultraviolet-A and -B radiation as well as by ionizing radiation. Radiation therapy (RT) for other conditions, especially at a young age, is also associated with an increased risk for developing


BCC.<sup>23-27</sup> Most BCC tumors develop on skin sites exposed to radiation—either from the sun or from therapy.<sup>23-25</sup>

## Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Basal Cell Skin Cancer, an electronic search of the PubMed database was performed to obtain key literature using the following search term: *basal cell skin carcinoma*. The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.<sup>28</sup>

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial; Guideline; Meta-Analysis; Practice Guideline; Randomized Controlled Trial; Systematic Reviews; and Validation Studies.

The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines as discussed by the panel during the Guidelines update have been included in this version of the discussion section. Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.



Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-2

## Sensitive/Inclusive Language


NCCN Guidelines strive to use language that advances the goals of equity, inclusion, and representation.<sup>29</sup> NCCN Guidelines endeavor to use language that is person-first; not stigmatizing; antiracist, anticlassist, antisogynist, antiageist, antiablist, and antiweight biased; and inclusive of individuals of all sexual orientations and gender identities. NCCN Guidelines incorporate nongendered language, instead focusing on organ-specific recommendations. This language is both more accurate and more inclusive and can help fully address the needs of individuals of all sexual orientations and gender identities. NCCN Guidelines will continue to use the terms men, women, female, and male when citing statistics, recommendations, or data from organizations or sources that do not use inclusive terms. Most studies do not report how sex and gender data are collected and use these terms interchangeably or inconsistently. If sources do not differentiate gender from sex assigned at birth or organs present, the information is presumed to predominantly represent cisgender individuals. NCCN encourages researchers to collect more specific data in future studies and organizations to use more inclusive and accurate language in their future analyses.

## Genetics

Extensive research has led to advances in the understanding of the genetics of BCC. The sonic hedgehog signaling pathway has emerged as playing a pivotal role in the pathogenesis of BCC, and mutations in a number of molecules in this pathway have been implicated in the development of the disease.<sup>30–32</sup> Mutations in the *PTCH1* (patched 1) gene on chromosome 9q, which codes for the sonic hedgehog receptor, are the underlying cause of nevoid BCC syndrome and are present in approximately 30%–90% of sporadic BCCs.<sup>33–41</sup> Specific ultraviolet-induced mutations in the tumor suppressor gene *p53* appear to be a common event in BCC development.<sup>35,38,41,42</sup> Certain genetic syndromes greatly predispose affected individuals to skin cancer formation, including BCC, such as albinism<sup>43,44</sup> and xeroderma pigmentosum (in which defects exist in ultraviolet light-induced unscheduled DNA repair).<sup>45–51</sup>

## Clinical Presentation and Workup

On clinical presentation of the patient with lesion suspicious of skin cancer, workup for BCC begins with a history and physical examination, biopsy, and if applicable a shave removal. A skin biopsy is then performed on any suspicious lesion. The biopsy should include deep reticular



BCC-3

dermis. This procedure is preferred because an infiltrative histology may sometimes be present only at the deeper, advancing margins of a tumor, and superficial biopsies will frequently miss this component.<sup>52,53</sup> After BCC diagnosis, a full skin examination is recommended, because individuals with skin cancer often have additional, concurrent precancers or cancers located at other, usually sun-exposed skin sites. These individuals are also at increased risk of developing cutaneous melanoma.<sup>54</sup>

### Risk Stratification of Local BCC Based on Risk Factors for Recurrence


After the complete skin examination, a risk assessment should be performed to determine the treatment plan.<sup>55</sup> The NCCN Panel examined risk factors for BCC associated with recurrence (see “Risk Factors for Recurrence” in the algorithm). Any high-risk factor places the skin lesion in the high-risk category, and imaging should be considered if a clinical exam is insufficient to determine disease extent. Skin lesions in populations placed at increased risk may be difficult to assess clinically; therefore, a low threshold for performing skin biopsies in these patients is necessary. Patients with locally advanced disease, which is defined as primary or recurrent extensive disease where surgery and/or RT may not result in a cure or

would potentially yield a significant functional limitation, should consider imaging to determine disease extent. For rare cases when patients present with regional or distant metastatic disease at diagnosis, imaging of areas of interest can be performed when there is suspicion of extensive disease before treatment as nodal or distant metastases. Imaging studies may be clinically evident when extensive disease, such as bone involvement, perineural invasion (PNI), or deep soft tissue involvement, is suspected. If perineural disease is suspected, MRI with or without contrast is preferred.<sup>56,57</sup> If bone disease is suspected, CT with contrast is preferred unless contraindicated. Imaging modality and targeted area should be at the discretion of the treating team based on the suspected extent of disease (ie, local, regional, metastatic). Histologic confirmation is sufficient to diagnose local recurrence, but MRI can be considered to assess extent of local disease. For nodal or distant metastases, histologic analysis and/or CT imaging can be used for confirmation and to gauge the extent of disease.

### History and Physical Examination

#### Location and Size

Anatomic location<sup>58-64</sup> and size<sup>60-66</sup> have been known to be a risk factor for BCC recurrence and metastasis for



Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-4

many years. In general, BCCs that develop in the head and neck area, which includes the “H zone” or “mask area” of the face, are more likely to recur than those that develop on the trunk and extremities. Based on a 27-year retrospective review of 5,755 BCCs, recurrences were significantly more common when tumors in high-risk locations (central face, eyebrows, nose, lips, chin, ear, temple, genitalia, nipples/areola, hands, feet, ankles, and nail units) were  $\geq 6$  mm in diameter and when tumors in moderate-risk locations (cheeks, forehead, scalp, neck, jawline, pretibial surface) were  $\geq 10$  mm in diameter.<sup>67</sup> The American Academy of Dermatology in collaboration with American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and American Society for Mohs Surgery developed an appropriate use criteria document in the treatment of cutaneous neoplasms based on 270 clinical scenarios including 69 BCCs,<sup>68</sup> which has been incorporated into “Risk Factors for Recurrence” within the algorithm.

### Clinical Borders and Primary Versus Recurrent Disease

The low- and high-risk factors of well-defined versus ill-defined clinical tumor borders<sup>69–71</sup> and primary versus recurrent disease,<sup>62,70,72</sup> respectively, have been extensively documented in the literature.

### Immunosuppression


Settings of immunosuppression, such as organ transplantation,<sup>73–78</sup> and long-term use of psoralen and ultraviolet-A light,<sup>79,80</sup> increase the incidence of BCC. In particular, among patients who have had organ transplants, BCC incidence is approximately 5- to 10-fold higher than in the general population,<sup>81–83</sup> occurring in up to half of patients during the 10 years after transplant.<sup>84–87</sup> Several large retrospective studies found that BCCs in patients who had received organ transplants were more likely to have the superficial histologic subtype and to occur in extracephalic locations and in younger patients (mean age of onset 15 years lower).<sup>88–90</sup> Two of these studies showed similar low recurrence rates for transplant recipients and controls.<sup>89,90</sup> Nevertheless, because of NCCN Guidelines Panel Members’ own anecdotal experiences, the panel decided to classify BCCs developing in settings of immunosuppression as potentially high-risk tumors.

### Site of Prior Radiotherapy

Tumors developing in sites of prior RT refer to primary BCCs arising in areas previously irradiated for unrelated conditions. All recurrent tumors, irrespective of prior therapy, are defined as high risk. Data from a number of studies with large sample sizes support that prior RT for unrelated, frequently benign conditions is a risk factor for BCC development.<sup>23–27,91,92</sup>

## FOLLOW-UP

## RECURRENCE



<sup>x</sup> Follow-up with a dermatologist is strongly recommended if any of the following criteria are met: past or imminent solid organ, marrow, or hematopoietic cell transplant; one or more cutaneous melanomas in the past 5 years; or four or more non-melanoma skin cancers in the past 5 years.

<sup>y</sup> Imaging modality and targeted area should be at the discretion of the treating team based on the suspected extent of disease (ie, local, regional, metastatic). Histologic confirmation is sufficient to diagnose local recurrence, but MRI can be considered to assess extent of local disease. For nodal or distant metastasis, histologic analysis and/or CT imaging can be used for confirmation and to gauge extent of disease.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-5

## Pathology

## Pathologic Subtypes

Histologic subtyping of BCC as a predictor of risk of recurrence is a well-established concept.<sup>93,94</sup> The subtypes encompassed by the term “aggressive growth pattern,” including micronodular, infiltrative, sclerosing, and morpheaform (or desmoplastic) patterns, are more likely to recur than the nodular and superficial BCC.<sup>65,69,70,72,95–99</sup>

Nonaggressive subtypes include the keratotic variant, infundibulocystic variant, and fibroepithelioma of Pinkus.

Basosquamous carcinomas are tumors that have the histologic appearance of both a BCC and an SCC. Some basosquamous tumors are the result of a BCC colliding with an adjacent SCC. Others represent truly biphenotypic tumors, many of which may have started as BCC, but have subsequently undergone prominent partial squamous metaplasia.<sup>100</sup> Data suggest that basosquamous carcinomas have a metastatic capacity that is more similar to that of SCC than BCC.<sup>101–103</sup>

## Perineural Involvement

PNI is uncommon in any nonmelanoma skin cancer (NMSC) (2%–6%), and develops less frequently and is less aggressive in BCC versus SCC.<sup>104–109</sup> BCC with PNI poses a greatly increased risk of recurrence and is associated

with other risk factors including previous recurrent tumors, high grade, larger lesion size, and certain subtypes (infiltrating, morpheaform, and basosquamous).<sup>108,110,111</sup>

If large nerve involvement is suspected, MRI should be considered to evaluate extent and/or rule out skull involvement in those with head and neck tumors.<sup>57,112–114</sup>

Additionally, in the presence of PNI, a thorough cranial nerve exam is indicated.

## Age and its Effect on BCC Behavior

Whether young age (typically aged ≤40 years) is an independent risk factor for aggressive BCC behavior is debatable. An analysis of a large database of patients with BCC (n=3,381) documented an increased percentage of BCC with aggressive histologic growth patterns in young persons.<sup>115</sup> In contrast, results from other analyses of large databases (n=1,000 to >10,000) indicate that patients presenting with BCC at a young age are more likely to have the superficial subtype.<sup>116–119</sup> Other analyses report no significant differences in BCC histologic subtype between young versus older patients.<sup>120–122</sup> The relationship between tumor location and patient age is also unclear, because several studies showed that younger patients were more likely to present with BCCs on the trunk or extremities,<sup>116,121,123,124</sup> while another found no significant association.<sup>120</sup>

## PRINCIPLES OF PATHOLOGY

**Principles of Biopsy Reporting:**

- The intent of a biopsy is for diagnosis, not to assess the margin status.
- Pathologic evaluation of skin biopsies is ideally performed by a dermatologist, pathologist, dermatopathologist, or Mohs surgeon who is experienced in interpreting cutaneous neoplasms.
- Clinical information to be submitted on biopsy requisition includes patient age and gender, clinical diameter of lesion, anatomic location, and prior treatment of lesion. Additional helpful features to include are immunosuppression and history of RT.
- Pathologic report should include histologic subtype<sup>a</sup> and presence and extent of any features that would increase the risk for local recurrence, including invasion of tumor beyond reticular dermis and presence of perineural invasion.<sup>1</sup>

**Principles of Excision Reporting:**

- The intent of excision is to clear the tumor and thus margin status needs to be reported.
- Saucerization specimens intended for definitive surgical therapy should be labeled as such, as they can be histopathologically difficult to distinguish from shave biopsies but must be evaluated for margin status.
- Clinical information to be submitted on excision requisition includes patient age and gender, anatomic location, clinical diameter of lesion, and additional clinical information listed above under Principles of Biopsy Reporting.
- Minimal reporting elements to be reported for all surgical specimens include histologic subtype of BCC,<sup>a</sup> invasion of tumor beyond deep reticular dermis, presence of perineural invasion (if involving nerve below dermis or if largest nerve involved is  $\geq 0.1$  mm in caliber) and angiolymphatic invasion, and peripheral and deep margin status.
- For Mohs excisions, reporting of these elements is also encouraged. Since depth of invasion (in mm) may not be ascertained on tangentially cut Mohs specimens, anatomic level of invasion should be reported. Frozen or permanent section analysis of the clinical tumor specimen may be undertaken if needed for complete reporting of features associated with poor prognosis.<sup>2</sup>

**Footnotes**

<sup>a</sup> Low-risk histologic subtypes include nodular, superficial, and other non-aggressive growth patterns such as keratotic, infundibulocystic, and fibroepithelioma of Pinkus; high-risk subtypes include basosquamous, infiltrative, sclerosing/morpheaform, micronodular, and BCC with carcinosarcomatous differentiation.

**References**

<sup>1</sup> Work Group; Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of basal cell carcinoma. *J Am Acad Dermatol* 2018;78:540-559.

<sup>2</sup> Morgan FC, Ruiz ES, Karia PS, et al. Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. *J Am Acad Dermatol* 2021;85:582-587.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-A

Most large studies (n=50–2,000) have shown no significant association between age and recurrence rate.<sup>62,70,120,122</sup> One multivariate analysis, however, showed a positive relationship between increasing age and likelihood of recurrence.<sup>125</sup> Age has also been evaluated as a risk factor for developing a second or multiple BCCs and many of these studies using fairly large databases (n=200–2,500) found that the risk of developing more than one BCC is associated with increased age.<sup>65,122,124–130</sup> On the contrary, an analysis of a very large database (n=71,924) found a significantly higher risk of subsequent NMSC in patients aged <40 years at the time of their first BCC diagnosis.<sup>131</sup> In addition, an analysis of 100 meta-static BCC cases found that patients with distant metastases tended to be younger than those with only regional metastases.<sup>132</sup> Consistent with this idea, the Rotterdam Study showed that although the risk of developing a second BCC increased with age,<sup>130</sup> the risk of developing multiple BCC lesions was highest in patients who were aged <65 years at the time of their first BCC diagnosis.<sup>133</sup> Taken together, these studies suggest that young age, in and of itself, is not considered a risk factor for aggressive BCC. Nevertheless, there is a small subset of patients who develop BCC at a young age and may have particularly aggressive disease. These patients may benefit from regular follow-up.

**Treatment Modalities for BCC****Curettage and Electrodesiccation**

Although a fast and cost-effective technique for superficial lesions, curettage and electrodesiccation (C&E) does not allow histologic margin assessment. Studies have reported overall 5-year recurrence rates ranging from 1.2% to 40% in patients with BCC selected for C&E, with high-risk locations and histologically aggressive subtypes reporting higher recurrence rates.<sup>60,134–143</sup>

This technique is deemed effective for properly selected, low-risk BCC with 3 caveats.<sup>60,140</sup> First, C&E should not be used to treat areas with terminal hair growth such as the scalp, pubic and axillary regions, or beard area due to the risk that a tumor extending down follicular structures might not be adequately removed. Second, if the subcutaneous layer is reached during the course of C&E, then surgical removal should generally be performed instead. This change in therapy is necessary because the effectiveness of the C&E technique rests on the ability of the clinician to distinguish between firm normal dermis and soft tumor tissue when using a sharp curette. Since subcutaneous adipose is even softer than tumor tissue, the ability of the curette to distinguish and, therefore, selectively and completely remove tumor cells diminishes. Third, if C&E has been performed

STRATIFICATION TO DETERMINE TREATMENT OPTIONS FOR LOCAL BCC BASED ON RISK FACTORS FOR RECURRENCE<sup>a</sup>

| Risk Group             | Low Risk                          | High Risk                                                                                                   |
|------------------------|-----------------------------------|-------------------------------------------------------------------------------------------------------------|
| Treatment options      | <b>BCC-2</b>                      | <b>BCC-3</b>                                                                                                |
| H&P                    |                                   |                                                                                                             |
| Location/size          | Trunk, extremities <2 cm          | Trunk, extremities ≥2 cm<br>Head, neck, hands, feet, pretibial, and anogenital area (any size) <sup>c</sup> |
| Borders                | Well-defined                      | Poorly defined                                                                                              |
| Primary vs. recurrent  | Primary                           | Recurrent                                                                                                   |
| Immunosuppression      | (-)                               | (+)                                                                                                         |
| Site of prior RT       | (-)                               | (+)                                                                                                         |
| Pathology (BCC-A)      |                                   |                                                                                                             |
| Subtype                | Nodular, superficial <sup>b</sup> | Aggressive growth pattern <sup>d</sup>                                                                      |
| Perineural involvement | (-)                               | (+)                                                                                                         |

<sup>a</sup> Any high-risk factor places the patient in the high-risk category.

<sup>b</sup> Low-risk histologic subtypes include nodular, superficial, and other non-aggressive growth patterns such as keratotic, infundibulocystic, and fibroepithelioma of Pinkus.

<sup>c</sup> This area constitutes high risk based on location, independent of size. Narrow excision margins due to anatomic and functional constraints are associated with increased recurrence rates with standard histologic processing. Complete margin assessment such as with Mohs or PDEMA is recommended for optimal tumor clearance and maximal tissue conservation. For tumors <6 mm in size, without other high-risk features, other treatment modalities may be considered if at least 4-mm clinically tumor-free margins can be obtained without significant anatomic or functional distortions.

<sup>d</sup> Having basosquamous, infiltrative, sclerosing/morpheaform, micronodular, and BCC with carcinosarcomatous differentiation features in any portion of the tumor. In some cases, basosquamous tumors may be prognostically similar to squamous cell carcinoma (SCC); clinicopathologic correlation is recommended in these cases to further consider prognostic implication.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-B

based only on the appearance of a low-risk tumor, biopsy results of the tissue taken at the time of C&E should be reviewed to make sure that there are no high-risk pathologic features that would require additional therapy. For tumors on the cheeks, forehead, scalp, neck, and pretibial that are less than 6 mm in depth and confined to the dermis, C&E may be considered as an alternative primary treatment option if Mohs micrographic surgery (Mohs) or resection with peripheral and deep en face margin assessment (PDEMA) and standard excision are not feasible due to patient comorbidities.

### Shave Removal

Shave removal, the shaving of epidermal or dermal lesions, is a sharp removal by bowl-shaped slicing of the epidermal and dermal lesions, without including fat, and does not require suture closure.<sup>144</sup> Like C&E, there is concern for inaccurate margin status assessment with shave removal.<sup>145</sup> However, it is a recommended technique for low-risk BCCs located in the trunk or extremities. Shave removal studies have reported 0.5%–30% rate of recurrence over a 3- to 5-year follow-up, multiple tumors treated in single visits, and a risk for misdiagnosis of only 1%.<sup>144–147</sup>

### Standard Excision With Postoperative Margin Assessment

Another therapeutic option for BCC is standard surgical excision followed by postoperative pathologic evaluation of margins. This technique has been reported to achieve 5-year recurrence rates of 0.8%–17.4% for BCC, with lower recurrence rates associated with low-risk tumors and higher recurrence rates associated with high-risk tumors.<sup>134,136,142,148–150</sup> Studies have reported variable margins required to completely excise 95% of all tumor.<sup>151–156</sup> These margins have been suggested to be 2 to 4 mm for low-risk, well-demarcated tumors smaller than 2 cm,<sup>151–155</sup> whereas margins of 4 to 6 mm,<sup>152</sup> and in one study, 8 mm,<sup>151</sup> were suggested for high-risk BCC. Given this wide variability, studies have reported incomplete excision rates after standard excision ranging from 3.2% to 61.5% depending on tumor location, histologic subtype, and medical provider's specialty.<sup>157–166</sup> Therefore, postoperative margin assessment and identification of clear margins are critical to ensure favorable outcomes with standard excision.

The clinical margins chosen by the panel for the primary treatment of low-risk BCC are based on the work of Zitelli et al.<sup>167</sup> Their analysis indicated that for well-circumscribed BCC lesions smaller than 2 cm in diameter, excision with 4-mm clinical margins should result in complete removal in more than 95% of cases. The indications

## PRINCIPLES OF TREATMENT

- The primary treatment goals of BCC is the complete removal of the tumor and the maximal preservation of function and cosmesis. All treatment decisions should be customized to account for the particular factors present in the individual case and for the patient's preference.
- Surgical approaches often offer the most effective and efficient means for accomplishing cure, but considerations of function, cosmesis, and patient preference may lead to choosing RT/topical therapy/systemic therapy as primary treatment in order to achieve optimal overall results.
- In certain patients at high risk for multiple primary tumors (eg, basal cell nevus syndrome [Gorlin syndrome], xeroderma pigmentosum, history of RT), increased surveillance and consideration of prophylactic measures may be indicated. Refer patients with suspected basal cell nevus syndrome or xeroderma pigmentosum for genetic evaluation.
- In patients with superficial basal cell skin cancer, non-surgical modalities may be considered. (See BCC-2)
- When Mohs<sup>b</sup> with margin assessment is being performed and the preoperative biopsy is considered insufficient for providing all the staging information required to properly treat the tumor, submission of the central specimen for vertical paraffin-embedded permanent sections or documentation of staging parameters in Mohs report is recommended.
- Use of nicotinamide may be effective in reducing the development of basal cell skin cancers.<sup>1,2</sup>

## Footnotes

<sup>a</sup> Cure rates are approximately 10% lower than for surgical treatment modalities. Jansen MHE, Mosterd K, Arits AHMM, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. *J Invest Dermatol* 2018;138:527-533. Drew BA, Karia PS, Mora AN, et al. Treatment patterns, outcomes, and patient satisfaction of primary epidermally limited nonmelanoma skin cancer. *Dermatol Surg* 2017;43:1423-1430.

<sup>b</sup> Mohs surgery should be performed by dermatologic surgeons who have specialized training and experience in this procedure.

## References

<sup>1</sup> Chen AC, Martin AJ, Dalziel RA, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. *Br J Dermatol* 2016;175:1073-1075.

<sup>2</sup> Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. *N Engl J Med* 2015;373:1618-1626.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-C

for this approach were also expanded to include re-excision of low-risk primary BCC if positive margins are obtained after an initial excision with postoperative margin assessment. For high-risk BCC, standard excision with wider surgical margins is recommended as the primary treatment. Due to the wide variability of clinical characteristics that may define a high-risk tumor, it is not feasible to recommend a defined margin for standard excision of high-risk BCC. Keen awareness of the subclinical extension of BCC is advised when selecting a treatment modality without complete margin assessment for a high-risk tumor. These margins may need to be modified based on tumor- or patient-specific factors. When standard excision with wider surgical margins yields positive margins, Mohs or other forms of PDEMA or standard re-excision are recommended (if PDEMA is not feasible).

For either low-risk or high-risk BCC, when standard excision is used, tissue rearrangement (eg, flap reconstruction, extensive undermining) should not be undertaken until clear margins are identified. Second intention healing, linear repair, or skin graft are acceptable options.

## Mohs and PDEMA

Mohs is the preferred surgical technique over standard excision for re-excision of low-risk BCC after positive margins with standard excision, as well as the primary

surgical technique of choice for high-risk BCC because it allows intraoperative analysis of 100% of the excision margin. Mohs is also recommended when standard excision with wider surgical margins is unable to achieve negative margins in high-risk BCC. Two meta-analyses published in 1,989 associated Mohs with 5-year recurrence rates of 1.0% for primary BCC, and 5.6% for recurrent BCC.<sup>134,142</sup> In these studies, the recurrence rates for Mohs were lower than those for standard excision (10.1% and 17.4% for primary and recurrent BCC, respectively), and lower than those for any other treatment modality included in the analysis (C&E, cryotherapy, and RT).<sup>134,142</sup> Studies on the long-term outcomes (~4 years) of Mohs have reported overall recurrence rates of 2.9%–3.8%,<sup>168,169</sup> specifically 0%–6.5% for primary and 4%–20% for recurrent BCCs.<sup>94,170–175</sup> The only prospective randomized trial comparing Mohs to standard excision reported fewer 10-year recurrences with Mohs for both primary (2.5% vs 4.1%;  $P=.397$ ) and recurrent BCC (2.4% vs 12.1%;  $P=.015$ ), although the difference was only statistically significant for recurrent tumors. Importantly, a large proportion of recurrences occurred more than 5 years after treatment.<sup>143,176,177</sup> Besides lower recurrence rates, Mohs has also been associated with significant tissue sparing compared with standard excision.<sup>178,179</sup> It has been demonstrated that H-zone location, recurrent tumor, aggressive subtype, PNI, and

## PRINCIPLES OF RADIATION THERAPY

**General Principles<sup>a</sup>**

- Protracted fractionation is associated with improved cosmetic results and should be utilized for poorly vascularized or cartilaginous areas.
- RT is contraindicated for genetic conditions predisposing to skin cancer (eg, basal cell nevus syndrome and relatively contraindicated for patients with connective tissue diseases (eg, scleroderma).
- Given higher complication rates, re-irradiation should not be routinely utilized for recurrent disease within a prior radiation field.
- Isotope-based brachytherapy can be an effective treatment for certain sites of disease, particularly on the head and neck.
- There are insufficient long-term efficacy and safety data to support the routine use of electronic surface brachytherapy.

**General Treatment Information**

- Radiation treatments should be given by a practicing radiation oncologist with radiation physics support to meet established quality assurance and dosimetric constraints.

| Primary Tumor                                                                                                                                                                            | RT Dosing                                                                                   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Definitive RT                                                                                                                                                                            | BED10 of 70–93 Gy for conventional fractionation<br>BED10 of 56–88 Gy for hypofractionation |
| Postoperative adjuvant RT                                                                                                                                                                | BED10 of 60–79 Gy for conventional fractionation<br>BED10 of 56–70 Gy for hypofractionation |
| Regional Disease                                                                                                                                                                         |                                                                                             |
| • Lymph node regions, after lymph node dissection <ul style="list-style-type: none"> <li>▶ Negative margins, no extranodal extension (ENE)</li> <li>▶ Positive margins or ENE</li> </ul> | 50–60 Gy over 5 to 6 weeks<br>60–66 Gy over 6 to 7 weeks                                    |
| • Lymph node regions, without lymph node dissection <ul style="list-style-type: none"> <li>▶ Clinically positive</li> </ul>                                                              | 60–70 Gy over 6 to 7 weeks                                                                  |
| • Clinically at-risk nerves                                                                                                                                                              | 50–60 Gy over 5 to 6 weeks                                                                  |

- BED = Biologically effective dose
- Conventionally fractionated radiotherapy consists of five daily treatments per week.
- Hypofractionated radiotherapy consists of daily treatments or two to four treatments per week. Fraction sizes larger than 6 Gy are not routinely recommended outside of the palliative setting.

<sup>a</sup> ASTRO Guideline on Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-D

tumor size greater than or equal to 11 mm are significantly associated with two or more Mohs stages.<sup>110,180</sup> However, superficial BCC, despite being generally considered less aggressive, was shown in a Brazilian study to be 9.03 times more likely to require more than one Mohs stage, likely due to “skip areas” and clinically indistinct borders.<sup>181</sup>

Excision with PDEMA with permanent section analysis or intraoperative frozen section analysis is an acceptable alternative to Mohs provided it includes a complete assessment of all deep and peripheral margins. A 5-year recurrence rate of 0.58% has been reported with slow Mohs using formalin-fixed paraffin-embedded sections and delayed closure in a UK-based prospective study.<sup>182</sup> The descriptive term PDEMA underscores the panel’s belief that complete histologic assessment of the entire marginal surface is the key to optimal tumor removal. For more information, refer to the NCCN Guidelines for Squamous Cell Skin Cancer (available at NCCN.org).

### Radiation Therapy

Although surgery is the mainstay of local treatment for BCC, consideration of function and patient preference and other factors may lead to the choice of RT as primary therapy for nonsurgical candidates for both low-risk and high-risk disease and patients with advanced BCC (locally

advanced, nodal, and metastatic BCC).<sup>183</sup> The recommendations for RT extend to additional treatment of low-risk BCC after positive margins with standard excision. RT is also recommended for high-risk BCC as additional treatment after standard excision, Mohs, or other forms of PDEMA with positive margins and adjuvant treatment after negative margins in case of extensive perineural or large-nerve involvement.<sup>184</sup> In these patients, local control has been reported to be 50%–90% with postoperative RT.<sup>183,185</sup> There are conflicting data about the value of adjuvant RT after margin-negative surgical excision, particularly after Mohs. For patients with high-risk BCC who have undergone multiple resections and for whom further surgery is not feasible, RT is recommended as part of multidisciplinary consultation if residual disease is present. For specifics about the application of RT, see “Principles of Radiation Therapy” in the algorithm.

Two meta-analyses reported 5-year recurrence rates of 8.7% and 9.8% after RT on primary and recurrent BCC, respectively.<sup>134,142</sup> Retrospective analyses of BCC treated with RT have reported 5-year local control, cure, or complete response rates ranging from 93% to 96%,<sup>186–189</sup> and 5-year recurrence rates from 4% to 16%.<sup>190–192</sup> Efficacy of RT was better for BCCs that were less advanced, primary (vs recurrent), or with a smaller diameter or nodular histologic subtype.<sup>186,187,189–191</sup> A prospective study

## PRINCIPLES OF SYSTEMIC THERAPY

**Locally Advanced (laBCC), Nodal or Distant Metastatic Basal Cell Carcinoma (mBCC)**

- Systemic therapy may be considered for laBCC. Locally advanced disease is defined by those that have primary or recurrent extensive disease where surgery and/or RT may not result in a cure or would possibly produce a significant functional limitation.
- Systemic therapy may be considered for cases of nodal or distant metastatic disease, especially if surgery and RT are not feasible.
- Multidisciplinary consultation may be required to determine the best treatment approach and deem the tumor not amenable to surgery or RT.
- Hedgehog pathway inhibitors (HHIs)
  - Due to frequency of intolerable side effects associated with HHIs, drug holidays or other alternatives to daily dosing can be used to reduce side effects to improve adherence to therapy and quality of life.
  - HHIs may be considered for diffuse BCC formation (eg, basal cell nevus syndrome or other genetic forms of multiple BCC). HHIs are not FDA approved for basal cell nevus syndrome; however, they may be used off-label and are effective based on a randomized controlled trial.<sup>1</sup>
- The role of adjuvant systemic therapy for resected BCC is unclear and thus, adjuvant systemic therapy is best performed in a clinical trial setting.

|                                        | Preferred Regimens | Other Recommended Regimens                              | Useful in Certain Circumstances              |
|----------------------------------------|--------------------|---------------------------------------------------------|----------------------------------------------|
| Locally Advanced Disease - Neoadjuvant | • None             | • Vismodegib <sup>a,2</sup> (category 2B)               | • Cemiplimab-rwlc <sup>b</sup> (category 2B) |
| Locally Advanced Disease               | • None             | • Sonidegib <sup>3</sup><br>• Vismodegib <sup>4,5</sup> | • Cemiplimab-rwlc <sup>b,c,6</sup>           |
| Nodal Disease                          | • None             | • Vismodegib<br>• Sonidegib <sup>3</sup> (category 2B)  | • Cemiplimab-rwlc <sup>b</sup>               |
| Metastatic Disease                     | • None             | • Vismodegib <sup>4,5</sup>                             | • Cemiplimab-rwlc <sup>b,6</sup>             |

<sup>a</sup> In one study of 55 patients with laBCC, neoadjuvant administration of vismodegib before planned surgery allowed for a smaller surgical procedure in 71% of patients, although it carried a high (36.4%) recurrence risk.<sup>2</sup>

<sup>b</sup> Cemiplimab-rwlc is FDA approved for patients with laBCC or mBCC previously treated with an HHI or for whom an HHI is not appropriate.

<sup>c</sup> A multinational single-arm phase 2 trial, consisting of 84 patients with locally advanced BCC (local invasion precluding complete resection or in locations for which surgery may result in severe disfigurement or dysfunction) whose disease had progressed on or was intolerant to prior HHI therapy, was conducted. Thirty-one percent had an objective response, including 6% with a complete response. See Discussion.<sup>6</sup>

**References on  
BCC-E (2 of 2)**

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

**BCC-E  
1 OF 2**

randomizing 347 patients to receive either surgery (standard excision with free margins  $\geq 2$  mm from visible borders) or RT as primary treatment of BCC reported higher recurrence rates with RT than surgery (7.5% vs 0.7%;  $P=.003$ ),<sup>193</sup> poorer cosmetic outcomes, and more postoperative complications.<sup>194</sup>

A small number of prospective studies have reported high rates of tumor control with specific radiation dose fractionation regimens for small BCCs.<sup>193,195,196</sup> A systematic review and meta-analysis also reported hypofractionated RT regimens associated with positive cosmetic outcomes.<sup>197</sup> The panel recommends ranges of electron beam dose and fractionation that can be used for definite RT and postoperative adjuvant RT. Isotope-based brachytherapy can be an effective treatment for certain sites of disease, particularly on the head and neck.<sup>198–201</sup> However, there are insufficient long-term efficacy and safety data to support the routine use of electronic surface brachytherapy.<sup>202,203</sup>

### Superficial Therapies

In patients with superficial BCC, therapies such as topical imiquimod, topical 5-fluorouracil (5-FU), or photodynamic therapy (PDT) may be considered, although cure rates are approximately 10% lower than for surgical treatment modalities.<sup>204–206</sup> Another option for patients with

superficial BCC is cryotherapy.<sup>207</sup> These options are also recommended for patients for whom surgery or RT is contraindicated or impractical.

### Topical Therapies

Imiquimod was found to be effective for treating nodular and superficial BCC in randomized studies.<sup>208–213</sup> Two 5-year follow-up studies reported overall treatment success rates of 80.4% and 77.9%, respectively, in patients with superficial BCC treated with imiquimod.<sup>212,214</sup> Recurrence seems to be associated with tumor thickness.<sup>215</sup> A phase III randomized trial in patients with superficial or nodular BCC showed that imiquimod provided an 82.5% clinical success rate.<sup>216,217</sup> For all of these studies, tumors in the H-zone were excluded. Although the clinical success rate was significantly higher with surgical excision using a 4-mm margin (97.7%;  $P<.001$ ), cosmetic outcomes by dermatologic assessment were significantly better with imiquimod (excellent/good at 3-year follow-up: 61% vs 36%;  $P<.001$ ). Another topical cream with efficacy against BCC is 5-FU,<sup>218,219</sup> which has been shown in a large randomized trial to have a 5-year tumor-free survival probability of 70.0%.<sup>205,220,221</sup> Other studies have reported cure rates of up to 90% with this treatment.<sup>222–224</sup>

## REFERENCES

- <sup>1</sup> Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 2016;17:1720-1731.
- <sup>2</sup> Bertrand N, Guerreschi P, Basset-Seguín N, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma. *EClinicalMedicine* 2021;35:100844.
- <sup>3</sup> Dummer R, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. *Br J Dermatol* 2020;182:1369-1378.
- <sup>4</sup> Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med* 2012;366:2171-2179.
- <sup>5</sup> Dreno B, Basset-Seguín N, Caro I, Yue H, Schadendorf D. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. *Oncologist*. 2014;19:790-796.
- <sup>6</sup> Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. *Lancet Oncol*. 2021;22:848-857.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-E  
2 OF 2

### Photodynamic Therapy

PDT with photosensitizing agents including 5-aminolevulinic acid (ALA) and porfimer sodium is another option for superficial BCC.<sup>225-227</sup> Multiple randomized trials and a meta-analysis have shown that rates of excellent or good cosmetic outcomes were higher with PDT versus surgery, although surgery was superior to PDT in terms of disease control.<sup>149,228-235</sup> Data from clinical trials reported cure rates from 60% to 100% by PDT for patients with BCC.<sup>231,236-241</sup> Most of these studies have focused on the superficial and nodular histologic subtypes, and several have found higher cure rates for superficial versus nodular subtypes in both low- and high-risk locations.<sup>231,236,241</sup> Ulceration and thickness are associated with lower response to therapy,<sup>241</sup> and within the nodular subtype, cure rates are better with thinner lesions.<sup>230</sup> Clinical studies have demonstrated PDT activity against “difficult-to-treat” lesions, with a 24-month complete response rate of 78%.<sup>236,242</sup> Currently, PDT is being used at some NCCN Member Institutions for premalignant or superficial low-risk lesions on any location on the body, although response rates may be higher on the face and scalp.<sup>243,244</sup>

### Cryotherapy

Cryotherapy has been used for many years as a fast and cost-effective means for removal of BCCs.<sup>207</sup> Systematic

reviews of historical data in primary BCCs have reported recurrence rates for cryotherapy ranging from 0% to 13%, and mean recurrence rates from pooled analyses ranging between 3% and 4%.<sup>134,136,245,246</sup> In prospective trials, cryotherapy has been shown to result in recurrence rates ranging from 5% to 39%.<sup>195,247-249</sup> A key limitation of cryotherapy is poorer cosmetic outcomes compared with other treatment options, as demonstrated by prospective randomized trials.<sup>248-250</sup>

### Comparisons of Superficial Therapies

Several randomized studies and meta-analyses have compared superficial therapies for BCC (Table 1). In summary, these studies indicate that in patients with superficial BCC, PDT has similar efficacy as cryotherapy but much better cosmetic outcomes. Whereas a meta-analysis of 23 randomized and nonrandomized trials found no significant difference in efficacy for PDT versus imiquimod,<sup>251</sup> a randomized trial showed that treatment success was more likely with imiquimod.<sup>205,221</sup> This study also shows superior imiquimod outcomes compared with 5-FU cream. Exploratory subanalyses found that treatment success rates were significantly higher with imiquimod for tumors that are large or truncal, whereas PDT provided significantly better outcomes in older patients with lesions on the lower extremities.<sup>252</sup> Safety results showed that while PDT causes

## PRINCIPLES OF CANCER RISK ASSESSMENT AND COUNSELING

- The decision to offer genetic testing involves three related stages:
  - 1) Pre-test counseling prior to ordering testing;
  - 2) Consideration of the most appropriate testing strategy; and
  - 3) Testing result disclosure and post-test counseling.
- In certain patients at high risk for multiple primary tumors (eg, basal cell nevus syndrome, xeroderma pigmentosum, history of RT), increased surveillance and consideration of prophylactic measures may be indicated. Patients with these conditions should be referred to a cancer center with particular expertise in BCC prevention and prophylaxis.
- It is recommended that a genetic counselor, medical geneticist, endocrinologist, oncologist, surgeon, oncology nurse, or other health professional with expertise and experience in cancer genetics be involved at each stage whenever possible. Clinicians without direct referral access to the appropriate expertise should be aware of the telehealth genetic counseling options available. These resources can be found through the National Society of Genetic Counselors (NSGC) "Find a Genetic Counselor" tool ([www.nsgc.org](http://www.nsgc.org)).

See the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic<sup>†</sup> for the following:

- Principles of Cancer Risk Assessment and Counseling (EVAL-A<sup>†</sup>)
- Pedigree: First-, Second-, and Third-Degree Relatives of Proband (EVAL-B<sup>†</sup>)
- General Testing Criteria (CRIT-1<sup>†</sup>)

<sup>†</sup>To view the most recent version of these guidelines, visit [NCCN.org](http://NCCN.org).

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved.  
The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

BCC-F

moderate to severe pain during treatment administration, imiquimod and 5-FU are more likely to cause moderate to severe local swelling, erosion, crust formation, itching, and wound infections.<sup>220</sup> Both cryotherapy and PDT are associated with pain during and after treatment, and data from a randomized trial indicate a trend toward a higher likelihood of pain with PDT.<sup>248</sup>

### Nicotinamide in Reducing BCC Development

Data from phase II and phase III randomized trials indicated that treatment of actinic keratoses with nicotinamide reduced the occurrence of new BCCs, specifically by 20% at 12-month follow-up.<sup>253,254</sup> This is supported by data from another study.<sup>255</sup> Other agents that might be effective for the prevention of BCC in individuals at high risk for developing NMSCs include celecoxib,<sup>256</sup> acitretin,<sup>257</sup> capecitabine,<sup>258</sup> and tazarotene.<sup>259</sup>

### Systemic Therapy

For advanced BCC, systemic therapy is recommended as a treatment option for locally advanced (laBCC), metastatic (mBCC), and nodal BCC after multidisciplinary consultation. Other options include surgery, RT, and palliation and best supportive care for certain patients. The systemic therapy options for BCC include hedgehog pathway

inhibitor (HHI) and immunotherapy. Vismodegib and cemiplimab are currently recommended options for all advanced BCCs while sonidegib is only recommended for nodal and laBCC.

### Hedgehog Pathway Inhibitors

Vismodegib is an HHI approved by the US FDA for the treatment of adults with laBCC or mBCC that has recurred following surgery, or those who are not candidates for surgery or RT.<sup>260</sup> The 9-month follow-up data from the SHH4476g trial, a centrally reported, multicenter, phase I, open-label study, had an initial enrollment of 104 patients (laBCC, n=71; mBCC, n=33); however, pathology results excluded 8 patients with laBCC from the efficacy analysis (n=63). This trial reported an objective response rate of 30% in the mBCC group and 43% in the laBCC group, with a median duration of response (DOR) of 7.6 months and 9.5-month median progression-free survival.<sup>261</sup> A 39-month follow-up to these data from the ERIVANCE trial, an investigator-reported, multicenter, phase II trial, conveyed an objective response rate of 48.5% in the mBCC group and 60.3% in the laBCC group, with a median DOR of 14.8 months and 26.2 months for each group, respectively.<sup>261–264</sup> Results from these trials for vismodegib in BCC are summarized in Table 2.

| NCCN Categories of Evidence and Consensus |                                                                                                          |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------|
| <b>Category 1</b>                         | Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.    |
| <b>Category 2A</b>                        | Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.   |
| <b>Category 2B</b>                        | Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.           |
| <b>Category 3</b>                         | Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. |

All recommendations are category 2A unless otherwise indicated.

| NCCN Categories of Preference          |                                                                                                                                                             |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Preferred intervention</b>          | Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.                                              |
| <b>Other recommended intervention</b>  | Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes. |
| <b>Useful in certain circumstances</b> | Other interventions that may be used for selected patient populations (defined with recommendation).                                                        |

All recommendations are considered appropriate.

Version 2.2024, 09/14/2023 © 2023 National Comprehensive Cancer Network® (NCCN®). All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

CAT-1

According to these data, nearly all patients treated with vismodegib experienced at least one treatment-emergent adverse event, but a significant proportion of these were low grade (grade  $\leq 2$ ).<sup>261–263</sup> Serious adverse events occurred in 25%–32% of patients in these studies. The most common adverse events included muscle spasms, alopecia, taste loss, weight loss, decreased appetite, fatigue, nausea, and diarrhea.

Vismodegib has also been tested as BCC treatment and prophylaxis in patients with nevoid BCC syndrome. A randomized phase II study in patients with nevoid BCC syndrome and at least 10 operable BCC lesions found that vismodegib significantly reduced incidence of new BCC lesions compared with placebo, and also significantly reduced the size of existing lesions and the number of surgeries needed to remove BCC lesions.<sup>265–267</sup>

Sonidegib is another FDA-approved HHI agent for the treatment of patients with laBCC that has recurred following surgery or RT, or who are not candidates for surgery or RT.<sup>268</sup> Sonidegib is FDA approved for laBCC. The 42-month follow-up data from the centrally reported randomized, multicenter, phase II BOLT trial reported similar objective response rates for the 200-mg and 800-mg doses tested among patients with laBCC (56% and 46%, respectively), while there was a 2-fold difference for patients with mBCC (8% and 17%, respectively).<sup>269–273</sup> This trial also

reported, for each dose and patient group, median DOR and progression-free survival results that are summarized in Table 2. The 30-month investigator-reviewed data for the BOLT trial analyzing only the 200-mg dose showed a higher objective response rate of 71.2% for laBCC and 23.1% for mBCC (Table 2).<sup>271,274</sup> As with vismodegib, nearly all patients experienced at least one AE, and the most common AEs were muscle spasms, dysgeusia, alopecia, nausea, weight decrease, and fatigue. Elevated creatinine kinase was also frequently observed and was one of the most common grade 3–4 AEs, along with elevated lipase.

A key limitation to HHI therapies is that advanced BCC can develop resistance, which limits the DOR. A small investigator-initiated trial in patients with vismodegib-resistant advanced BCC observed no responses during treatment with sonidegib for a median of 6 weeks (range, 3–58 weeks), and in 5 of 9 patients with disease progression.<sup>275</sup>

Ongoing clinical research is exploring various dosing regimens of vismodegib and sonidegib in a variety of BCC treatment settings, including in the neoadjuvant setting, in patients with multiple BCCs or with radiation-induced multiple BCCs of the scalp, and as maintenance therapy after laBCC complete remission.<sup>276–281</sup> Notably, in the neoadjuvant setting, although one trial reported negative results (unmet predefined complete histologic clearance rate),<sup>277</sup> results from 2 studies indicated vismodegib may

**Table 1. Studies Comparing Superficial Therapies in Patients With Superficial BCC**

| Study                                                                      | Histologic Subtype      | Tumor Locations                        | Treatments (n)                                                     | Efficacy                         |                                                  | Cosmetic Outcome    |                                        |  |
|----------------------------------------------------------------------------|-------------------------|----------------------------------------|--------------------------------------------------------------------|----------------------------------|--------------------------------------------------|---------------------|----------------------------------------|--|
| Phase III randomized trial: Wang 2001 <sup>248</sup>                       | Superficial and nodular | Trunk, limb, head, neck                | Cryosurgery (39)<br>ALA-PDT (44)                                   | 1-year recurrence:               | 15%<br>25% } NS                                  | Excellent:          | 8%<br>50% } $P < .001$                 |  |
| Randomized trial: Basset-Seguín 2008 <sup>249</sup>                        | Superficial             | Trunk, limb, head, neck, face          | Cryotherapy (58)<br>MAL-PDT (60)                                   | 5-year recurrence:               | 20%<br>22% } NS                                  | Excellent:          | 16%<br>60% } $P = .00078$              |  |
| Meta-analysis: Roozeboom 2012 <sup>251</sup>                               | Superficial             | Locations depend on individual studies | Imiquimod (1,088)<br>PDT (934)                                     | 1-year tumor-free survival:      | 87%<br>84% } NS                                  | NR                  |                                        |  |
| Randomized, single-blind, noninferiority trial: Jansen 2018 <sup>205</sup> | Superficial             | Trunk, limb, head, neck                | MAL-PDT (202)<br>Imiquimod cream (198)<br>Fluorouracil cream (201) | Treatment success <sup>a</sup> : | 63%<br>81%<br>70% } $P < .001$<br>$P = .04$ } NS | Good/<br>Excellent: | 62%<br>61%<br>58% } All comparisons NS |  |

Abbreviations: MAL, methyl aminolevulinate; NR, not reported; NS, no statistically significant difference; PDT, photodynamic therapy.

<sup>a</sup>Treatment success was defined as the product of the percent of patients with clearance at 3 months by the percentage with sustained clearance during the next 9 months.

reduce surgical defect area and allow for downstaging of the surgical procedure for laBCCs in functionally sensitive locations.<sup>276,279</sup> The VISMEQ trial, a centrally reported, phase II, open-label study, had an enrollment of 55 patients with laBCC. This study reported an objective response rate of 71%, with 36.4% recurrence at the 3-year follow-up.<sup>279</sup> Some of these studies included small numbers of patients, and thus their results need to be carefully interpreted.

Other HHIs are also being tested in patients with BCC to see if they can provide higher rates of response,

more durable responses, responses in less advanced BCC, or responses in BCC resistant to vismodegib. Results from phase I–II trials with small BCC sample sizes ( $n < 40$ ) have shown that itraconazole and saridegib can elicit responses in patients with BCC, although not in patients who previously received vismodegib.<sup>282,283</sup>

### Immunotherapy

Cemiplimab-rwlc is an anti-PD-1 immunotherapy that is FDA-approved for patients with laBCC or mBCC who were previously treated with an HHI or for whom an HHI

**Table 2. Hedgehog Pathway Inhibitors in Advanced BCC<sup>a</sup>**

| Study                                                               |                     |                 | Patients<br>n |      | Objective<br>Response<br>Rate <sup>c</sup> |       | Duration of<br>Response,<br>Median <sup>d</sup> |           | Progression-free<br>Survival,<br>Median <sup>d</sup> |      | Overall<br>Survival,<br>Median <sup>d</sup> |      |
|---------------------------------------------------------------------|---------------------|-----------------|---------------|------|--------------------------------------------|-------|-------------------------------------------------|-----------|------------------------------------------------------|------|---------------------------------------------|------|
| Name and References                                                 | Design              | Tx <sup>b</sup> | laBCC         | mBCC | laBCC                                      | mBCC  | laBCC                                           | mBCC      | laBCC                                                | mBCC | laBCC                                       | mBCC |
| BOLT – 42-month follow-up<br>NCT01327053 <sup>269,270,272,273</sup> | Phase II<br>RDB, CR | Soni,<br>200 mg | 66            | 13   | 56%                                        | 8%    | 26.1                                            | 24.0      | 22.1                                                 | 13.1 | NR                                          | NR   |
|                                                                     |                     | Soni,<br>800 mg | 128           | 23   | 46%                                        | 17%   | 23.3                                            | NE        | 24.9                                                 | 11.1 | NR                                          | NR   |
| BOLT – 30-month follow-up<br>NCT01327053 <sup>271,274</sup>         | Phase II<br>RBD, IR | Soni,<br>200 mg | 66            | 13   | 71%                                        | 23.1% | 15.7                                            | 17.7–18.4 | NR                                                   | NR   | NR                                          | NR   |
| SHH4476g – 9-month<br>follow-up<br>NCT00833417 <sup>261</sup>       | Phase I<br>OL, CR   | Vismo           | 63            | 33   | 43%                                        | 30%   | 7.6                                             | 7.6       | 9.5                                                  | 9.5  | NR                                          | NR   |
| ERIVANCE – 39-month<br>follow-up<br>NCT00833417 <sup>262–264</sup>  | Phase II<br>OL, IR  | Vismo           | 63            | 33   | 60%                                        | 49%   | 26.2                                            | 14.8      | 12.9                                                 | 9.3  | NE                                          | 33.4 |

Abbreviations: CR, centrally reviewed; IR, investigator reviewed; laBCC, locally advanced BCC; mBCC, metastatic BCC; NE, not reached; NR, not reported; OL, open-label; RDB, randomized double-blind; Soni, sonidegib; Tx, treatment; Vismo, vismodegib.

<sup>a</sup>Trials included patients with advanced BCC that was inappropriate for surgery or RT.

<sup>b</sup>Inhibitors were taken orally once daily. Vismodegib dose was 150 mg.

<sup>c</sup>Response criteria varied between studies.

<sup>d</sup>Times are reported in months.

is not appropriate.<sup>284</sup> Cemiplimab is a recommended treatment option for certain patients with advanced BCC including in the neoadjuvant setting for laBCC. A centrally reported, multicenter, phase II, open-label trial tested cemiplimab-rwlc (n=84) for patients with laBCC where local invasion precluding complete resection or in locations for which surgery may result in severe disfigurement or dysfunction and whose disease has progressed on or was intolerant to prior HHI therapy.<sup>285</sup> This study reported a median follow-up of 15 months, objective response rate of 31%, and grade 3–4 treatment-emergent adverse events in 48% of patients, while serious adverse events occurred in 35% of patients.<sup>285</sup>

Due to the rarity of advanced cases, the literature on chemotherapy for BCC is limited to case reports.<sup>286–292</sup>

### Follow-up

Follow-up for BCC should include a history and physical examination, along with a complete skin examination every 6 to 12 months for the first 5 years, and then at least annually for life. Imaging may be considered if clinical examination is insufficient for following the disease. Follow-up with a dermatologist is strongly recommended if any of the following criteria are met: past or imminent solid organ,

marrow, or hematopoietic cell transplant;  $\geq 1$  cutaneous melanomas in the past 5 years; or  $\geq 4$  NMSCs within the past 5 years.

Imaging modality and targeted area should be at the discretion of the treating team based on the suspected extent of disease (ie, local, regional, metastatic). Histologic confirmation is sufficient to diagnose local recurrence, but imaging can be considered to assess extent of disease. As part of follow-up, the patients should be educated on sun protection and self-examination. For local recurrence, the primary treatment pathway for high-risk BCC should be followed. For locally advanced, nodal metastases, and distant metastases, the appropriate path should be followed as found within “Advanced BCC” in the algorithm.

An estimated 30%–50% of patients with BCC will develop another BCC within 5 years.<sup>126,129,293–296</sup> This represents a 10-fold increase in risk compared with the general population.<sup>294</sup> Patients with a prior BCC are also at increased risk of developing SCC and cutaneous melanoma.<sup>126,296</sup> A prospective population-based cohort study found that development of a second BCC is most likely during the short-term follow-up period after diagnosis of the first lesion.<sup>133</sup> Therefore, close follow-up of patients with BCC in both the short- and long-term is critical.

### References

1. Asgari MM, Moffet HH, Ray GT, et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998–2012. *JAMA Dermatol* 2015;151:976–981.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7–30.
3. Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. *JAMA Dermatol* 2015;151:1081–1086.
4. Abbas M, Kalia S. Trends in non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) in Canada: a descriptive analysis of available data. *J Cutan Med Surg* 2016;20:166–175.
5. Rudolph C, Schnoor M, Eisemann N, et al. Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010. *J Dtsch Dermatol Ges* 2015;13:788–797.
6. Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota, 2000 to 2010. *Mayo Clin Proc* 2017;92:890–898.
7. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. *JAMA* 2005;294:681–690.
8. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. *J Am Acad Dermatol* 1984;10:1043–1060.
9. Nguyen-Nielsen M, Wang L, Pedersen L, et al. The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997–2010. *Eur J Dermatol* 2015;25:463–468.
10. Wadhera A, Fazio M, Bricca G, et al. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? *Dermatol Online J* 2006;12:7.
11. Krickler A, Armstrong BK, English DR, et al. Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. *Int J Cancer* 1995;60:489–494.
12. Krickler A, Armstrong BK, English DR, et al. A dose-response curve for sun exposure and basal cell carcinoma. *Int J Cancer* 1995;60:482–488.
13. Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-control study. *Br J Cancer* 2006;94:743–751.
14. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. *Arch Dermatol* 1995;131:157–163.
15. Ramsay HM, Fryer AA, Hawley CM, et al. Factors associated with non-melanoma skin cancer following renal transplantation in Queensland, Australia. *J Am Acad Dermatol* 2003;49:397–406.
16. Kaskel P, Lange U, Sander S, et al. Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany. *J Eur Acad Dermatol Venereol* 2015;29:134–142.
17. Khalesi M, Whiteman DC, Tran B, et al. A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. *Cancer Epidemiol* 2013;37:534–543.
18. Walther U, Kron M, Sander S, et al. Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor. *Br J Dermatol* 2004;151:170–178.
19. Box NF, Duffy DL, Irving RE, et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. *J Invest Dermatol* 2001;116:224–229.
20. Lock-Andersen J, Drzewiecki KT, Wulf HC. Eye and hair colour, skin type and constitutive skin pigmentation as risk factors for basal cell carcinoma and cutaneous malignant melanoma. A Danish case-control study. *Acta Derm Venereol* 1999;79:74–80.
21. Chinem VP, Miot HA. Prevalence of actinic skin lesions in patients with basal cell carcinoma of the head: a case-control study. *Rev Assoc Med Bras* (1992) 2012;58:188–196.
22. Wu S, Han J, Li WQ, et al. Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. *Am J Epidemiol* 2013;178:890–897.
23. Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. *J Clin Oncol* 2005;23:3733–3741.
24. Karagas MR, Nelson HH, Zens MS, et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and

- potential modification of risk by sun exposure. *Epidemiology* 2007;18:776–784.
25. Watt TC, Inskip PD, Stratton K, et al. Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study. *J Natl Cancer Inst* 2012;104:1240–1250.
  26. Schwartz JL, Kopecky KJ, Mathes RW, et al. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. *Radiat Res* 2009;171:155–163.
  27. Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. *J Natl Cancer Inst* 1996;88:1848–1853.
  28. National Institutes of Health. PubMed overview. Accessed September 1, 2023. Available at: <https://pubmed.ncbi.nlm.nih.gov/about/>
  29. Freedman-Cass DA, Fischer T, Alpert AB, et al. The value and process of inclusion: using sensitive, respectful, and inclusive language and images in NCCN content. *J Natl Compr Canc Netw* 2023;21:434–441.
  30. Lesiak A, Sobolewska-Sztychyn D, Majak P, et al. Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population. *Arch Dermatol Res* 2016;308:39–47.
  31. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. *Cancer Res* 1998;58:1798–1803.
  32. Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. *Nature* 1998;391:90–92.
  33. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. *Cell* 1992;69:111–117.
  34. Soufir N, Gerard B, Portela M, et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. *Br J Cancer* 2006;95:548–553.
  35. Ling G, Ahmadian A, Persson A, et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. *Oncogene* 2001;20:7770–7778.
  36. Heitzer E, Lassacher A, Quehenberger F, et al. UV fingerprints predominate in the PTCH mutation spectra of basal cell carcinomas independent of clinical phenotype. *J Invest Dermatol* 2007;127:2872–2881.
  37. Danaee H, Karagas MR, Kelsey KT, et al. Allelic loss at *Drosophila* patched gene is highly prevalent in basal and squamous cell carcinomas of the skin. *J Invest Dermatol* 2006;126:1152–1158.
  38. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. *Br J Dermatol* 2005;152:43–51.
  39. Kim MY, Park HJ, Baek SC, et al. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. *J Dermatol Sci* 2002;29:1–9.
  40. Gailani MR, Stähle-Bäcker M, Leffell DJ, et al. The role of the human homologue of *Drosophila* patched in sporadic basal cell carcinomas. *Nat Genet* 1996;14:78–81.
  41. Zhang H, Ping XL, Lee PK, et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. *Am J Pathol* 2001;158:381–385.
  42. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. *Proc Natl Acad Sci USA* 1993;90:4216–4220.
  43. Oluwasanmi JO, Williams AO, Alli AF. Superficial cancer in Nigeria. *Br J Cancer* 1969;23:714–728.
  44. Yakubu A, Mabogunje OA. Skin cancer in Zaria, Nigeria. *Trop Doct* 1995;25(Suppl 1):63–67.
  45. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. *Arch Dermatol* 1987;123:241–250.
  46. Bradford PT, Goldstein AM, Tamura D, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterizes the role of DNA repair. *J Med Genet* 2011;48:168–176.
  47. Kraemer KH, Lee MM, Andrews AD, et al. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. *Arch Dermatol* 1994;130:1018–1021.
  48. Kraemer KH, Lee MM, Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. *Carcinogenesis* 1984;5:511–514.
  49. Couvé-Privat S, Le Bret M, Traiffort E, et al. Functional analysis of novel sonic hedgehog gene mutations identified in basal cell carcinomas from xeroderma pigmentosum patients. *Cancer Res* 2004;64:3559–3565.
  50. Couvé-Privat S, Bouadjar B, Avril MF, et al. Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. *Cancer Res* 2002;62:7186–7189.
  51. Miller KL, Karagas MR, Kraft P, et al. XPA, haplotypes, and risk of basal and squamous cell carcinoma. *Carcinogenesis* 2006;27:1670–1675.
  52. Clements S, Khachemoun A. Upstaging of basal cell and squamous cell carcinomas during definitive surgery: a review of predictive preoperative clinical and histologic features. *Arch Dermatol Res* 2021;313:319–325.
  53. Singh B, Dorelles A, Konnikov N, et al. Detection of high-risk histologic features and tumor upstaging of nonmelanoma skin cancers on debulk analysis: a quantitative systematic review. *Dermatol Surg* 2017;43:1003–1011.
  54. Chen J, Ruczinski I, Jorgensen TJ, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. *J Natl Cancer Inst* 2008;100:1215–1222.
  55. Morgan FC, Ruiz ES, Karia PS, et al. Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death. *J Am Acad Dermatol* 2021;85:582–587.
  56. Gandhi MR, Panizza B, Kennedy D. Detecting and defining the anatomic extent of large nerve perineural spread of malignancy: comparing “targeted” MRI with the histologic findings following surgery. *Head Neck* 2011;33:469–475.
  57. Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. *Int J Radiat Oncol Biol Phys* 2001;49:1061–1069.
  58. Boeta-Angeles, Bennett RG. Features associated with recurrence (basal cell carcinoma). In: Miller SJ, Maloney ME, eds. *Cutaneous Oncology: Pathophysiology, Diagnosis, and Management*. Blackwell Science; 1998:pp. 646–656.
  59. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. *J Dermatol Surg Oncol* 1992;18:471–476.
  60. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: curettage-electrodesiccation. *J Dermatol Surg Oncol* 1991;17:720–726.
  61. Dubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. *Arch Dermatol* 1983;119:373–377.
  62. Bøgelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. *Acta Derm Venereol* 2007;87:330–334.
  63. Rigel DS, Robins P, Friedman RJ. Predicting recurrence of basal-cell carcinomas treated by microscopically controlled excision: a recurrence index score. *J Dermatol Surg Oncol* 1981;7:807–810.
  64. Spiller WF, Spiller RF. Treatment of basal cell epithelioma by curettage and electrodesiccation. *J Am Acad Dermatol* 1984;11:808–814.
  65. van Iersel CA, van de Velden HV, Kusters CD, et al. Prognostic factors for a subsequent basal cell carcinoma: implications for follow-up. *Br J Dermatol* 2005;153:1078–1080.
  66. Petrovich Z, Kuisk H, Langholz B, et al. Treatment results and patterns of failure in 646 patients with carcinoma of the eyelids, pinna, and nose. *Am J Surg* 1987;154:447–450.
  67. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 1: overview. *J Dermatol Surg Oncol* 1991;17:713–718.
  68. Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. *Dermatol Surg* 2012;38:1582–1603.
  69. Dixon AY, Lee SH, McGregor DH. Histologic features predictive of basal cell carcinoma recurrence: results of a multivariate analysis. *J Cutan Pathol* 1993;20:137–142.
  70. Jacobs GH, Rippey JJ, Altini M. Prediction of aggressive behavior in basal cell carcinoma. *Cancer* 1982;49:533–537.
  71. de Rosa G, Vettrani A, Zeppa P, et al. Comparative morphometric analysis of aggressive and ordinary basal cell carcinoma of the skin. *Cancer* 1990;65:544–549.
  72. Codazzi D, Van Der Velden J, Carminati M, et al. Positive compared with negative margins in a single-centre retrospective study on 3957

- consecutive excisions of basal cell carcinomas. Associated risk factors and preferred surgical management. *J Plast Surg Hand Surg* 2014;48:38–43.
73. Krynitz B, Olsson H, Lundh Rozell B, et al. Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study. *Br J Dermatol* 2016;174:95–103.
74. Mackintosh LJ, Geddes CC, Herd RM. Skin tumours in the West of Scotland renal transplant population. *Br J Dermatol* 2013;168:1047–1053.
75. Bernat García J, Morales Suárez-Varela M, Vilata JJ, et al. Risk factors for non-melanoma skin cancer in kidney transplant patients in a Spanish population in the Mediterranean region. *Acta Derm Venereol* 2013;93:422–427.
76. Karczewski M, Stronka M, Karczewski J, et al. Skin cancer following kidney transplantation: a single-center experience. *Transplant Proc* 2011;43:3760–3761.
77. Bordea C, Wojnarowska F, Millard PR, et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. *Transplantation* 2004;77:574–579.
78. DePry JL, Vyas R, Lazarus HM, et al. Cutaneous malignant neoplasms in hematopoietic cell transplant recipients: a systematic review. *JAMA Dermatol* 2015;151:775–782.
79. Stern RS, Liebman EJ, Våkevä L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. *J Natl Cancer Inst* 1998;90:1278–1284.
80. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen ultraviolet-A therapy and narrowband ultraviolet-B therapy in chronic plaque psoriasis: a systematic literature review. *J Eur Acad Dermatol Venereol* 2012;26(Suppl 3):22–31.
81. Park GH, Chang SE, Won CH, et al. Incidence of primary skin cancer after organ transplantation: an 18-year single-center experience in Korea. *J Am Acad Dermatol* 2014;70:465–472.
82. Jensen AO, Svaerke C, Farkas D, et al. Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. *Acta Derm Venereol* 2010;90:474–479.
83. Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in The Netherlands. *Transplantation* 1990;49:506–509.
84. Harwood CA, Mesher D, McGregor JM, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. *Am J Transplant* 2013;13:119–129.
85. Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. *Arch Dermatol* 2009;145:1391–1396.
86. Rashtak S, Dierkhising RA, Kremers WK, et al. Incidence and risk factors for skin cancer following lung transplantation. *J Am Acad Dermatol* 2015;72:92–98.
87. Fortina AB, Piaserico S, Caforio AL, et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. *Arch Dermatol* 2004;140:1079–1085.
88. Kanitakis J, Alhaj-Ibrahim L, Euvrard S, et al. Basal cell carcinomas developing in solid organ transplant recipients: clinicopathologic study of 176 cases. *Arch Dermatol* 2003;139:1133–1137.
89. Harwood CA, Proby CM, McGregor JM, et al. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. *J Am Acad Dermatol* 2006;54:290–300.
90. Lott DG, Manz R, Koch C, et al. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. *Transplantation* 2010;90:683–687.
91. Martin H, Strong E, Spiro RH. Radiation-induced skin cancer of the head and neck. *Cancer* 1970;25:61–71.
92. Lichter MD, Karagas MR, Mott LA, et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. *Arch Dermatol* 2000;136:1007–1011.
93. Dixon AY, Lee SH, McGregor DH. Factors predictive of recurrence of basal cell carcinoma. *Am J Dermatopathol* 1989;11:222–232.
94. Smeets NW, Kuijpers DI, Nelemans P, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face—results of a retrospective study and review of the literature. *Br J Dermatol* 2004;151:141–147.
95. Cigna E, Tarallo M, Maruccia M, et al. Basal cell carcinoma: 10 years of experience. *J Skin Cancer* 2011;2011:476362.
96. Szewczyk MP, Pazdrowski J, Dańczak-Pazdrowska A, et al. Analysis of selected recurrence risk factors after treatment of head and neck basal cell carcinoma. *Postepy Dermatol Alergol* 2014;31:146–151.
97. Bartoš V, Pokorný D, Zacharová O, et al. Recurrent basal cell carcinoma: a clinicopathological study and evaluation of histomorphological findings in primary and recurrent lesions. *Acta Dermatovenerol Alp Panonica Adriat* 2011;20:67–75.
98. Sartore L, Lancerotto L, Salmaso M, et al. Facial basal cell carcinoma: analysis of recurrence and follow-up strategies. *Oncol Rep* 2011;26:1423–1429.
99. Sloane JP. The value of typing basal cell carcinomas in predicting recurrence after surgical excision. *Br J Dermatol* 1977;96:127–132.
100. Costantino D, Lowe L, Brown DL. Basosquamous carcinoma—an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature. *J Plast Reconstr Aesthet Surg* 2006;59:424–428.
101. Martin RC 2nd, Edwards MJ, Cawte TG, et al. Basosquamous carcinoma: analysis of prognostic factors influencing recurrence. *Cancer* 2000;88:1365–1369.
102. Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. *J Am Acad Dermatol* 2009;60:137–143.
103. Wermker K, Roknic N, Goessling K, et al. Basosquamous carcinoma of the head and neck: clinical and histologic characteristics and their impact on disease progression. *Neoplasia* 2015;17:301–305.
104. Hassanein AM, Proper SA, Depcik-Smith ND, et al. Peritumoral fibrosis in basal cell and squamous cell carcinoma mimicking perineural invasion: potential pitfall in Mohs micrographic surgery. *Dermatol Surg* 2005;31:1101–1106.
105. Lin C, Tripcony L, Keller J, et al. Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. *Int J Radiat Oncol Biol Phys* 2012;82:334–340.
106. Garcia-Serra A, Hinerman RW, Mendenhall WM, et al. Carcinoma of the skin with perineural invasion. *Head Neck* 2003;25:1027–1033.
107. Lin C, Tripcony L, Keller J, et al. Cutaneous carcinoma of the head and neck with clinical features of perineural infiltration treated with radiotherapy. *Clin Oncol (R Coll Radiol)* 2013;25:362–367.
108. Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. *J Am Acad Dermatol* 2005;53:458–463.
109. Jackson JE, Dickie GJ, Wiltshire KL, et al. Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach. *Head Neck* 2009;31:604–610.
110. Ratner D, Lowe L, Johnson TM, et al. Perineural spread of basal cell carcinomas treated with Mohs micrographic surgery. *Cancer* 2000;88:1605–1613.
111. Brown CI, Perry AE. Incidence of perineural invasion in histologically aggressive types of basal cell carcinoma. *Am J Dermatopathol* 2000;22:123–125.
112. Galloway TJ, Morris CG, Mancuso AA, et al. Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion. *Cancer* 2005;103:1254–1257.
113. Balamucki CJ, DeJesus R, Galloway TJ, et al. Impact of radiographic findings on prognosis skin cancer with perineural invasion. *Am J Clin Oncol* 2015;38:248–251.
114. Cernea CR, Ferraz AR, de Castro IV, et al. Perineural invasion in aggressive skin carcinomas of the head and neck. Potentially dangerous but frequently overlooked. *ORL J Otorhinolaryngol Relat Spec* 2009;71:21–26.
115. Leffell DJ, Headington JT, Wong DS, et al. Aggressive-growth basal cell carcinoma in young adults. *Arch Dermatol* 1991;127:1663–1667.
116. McCormack CJ, Kelly JW, Dorevitch AP. Differences in age and body site distribution of the histological subtypes of basal cell carcinoma. A possible indicator of differing causes. *Arch Dermatol* 1997;133:593–596.
117. Bastiaens MT, Hoefnagel JJ, Bruijn JA, et al. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. *J Invest Dermatol* 1998;110:880–884.
118. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. *Br J Dermatol* 2002;147:41–47.
119. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. *Br J Dermatol* 2006;155:401–407.
120. Dinehart SM, Dodge R, Stanley WE, et al. Basal cell carcinoma treated with Mohs surgery. A comparison of 54 younger patients with 1050 older patients. *J Dermatol Surg Oncol* 1992;18:560–566.
121. Milroy CJ, Horlock N, Wilson GD, et al. Aggressive basal cell carcinoma in young patients: fact or fiction? *Br J Plast Surg* 2000;53:393–396.

122. Roudier-Pujol C, Aupein A, Nguyen T, et al. Basal cell carcinoma in young adults: not more aggressive than in older patients. *Dermatology* 1999;199:119–123.
123. Lear JT, Smith AG, Bowers B, et al. Truncal tumor site is associated with high risk of multiple basal cell carcinoma and is influenced by glutathione S-transferase, GSTT1, and cytochrome P450, CYP1A1 genotypes, and their interaction. *J Invest Dermatol* 1997;108:519–522.
124. Ramachandran S, Fryer AA, Lovatt T, et al. The rate of increase in the numbers of primary sporadic basal cell carcinomas during follow up is associated with age at first presentation. *Carcinogenesis* 2002;23:2051–2054.
125. Cheretis C, Angelidou E, Dietrich F, et al. Prognostic value of computer-assisted morphological and morphometrical analysis for detecting the recurrence tendency of basal cell carcinoma. *Med Sci Monit* 2008;14:MT13–MT19.
126. Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. *JAMA* 1992;267:3305–3310.
127. Lovatt TJ, Lear JT, Bastrilles J, et al. Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. *J Am Acad Dermatol* 2005;52:468–473.
128. Richmond-Sinclair NM, Pandeya N, Williams GM, et al. Clinical signs of photodamage are associated with basal cell carcinoma multiplicity and site: a 16-year longitudinal study. *Int J Cancer* 2010;127:2622–2629.
129. Flohil SC, Koljenović S, de Haas ER, et al. Cumulative risks and rates of subsequent basal cell carcinomas in the Netherlands. *Br J Dermatol* 2011;165:874–881.
130. Verkouteren JAC, Smedinga H, Steyerberg EW, et al. Predicting the Risk of a Second Basal Cell Carcinoma. *J Invest Dermatol* 2015;135:2649–2656.
131. Milán T, Pukkala E, Verkasalo PK, et al. Subsequent primary cancers after basal-cell carcinoma: a nationwide study in Finland from 1953 to 1995. *Int J Cancer* 2000;87:283–288.
132. McCusker M, Basset-Seguín N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. *Eur J Cancer* 2014;50:774–783.
133. Kiski V, de Vries E, Flohil SC, et al. Risk factors for single and multiple basal cell carcinomas. *Arch Dermatol* 2010;146:848–855.
134. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. *J Dermatol Surg Oncol* 1989;15:315–328.
135. Barlow JO, Zalla MJ, Kyle A, et al. Treatment of basal cell carcinoma with curettage alone. *J Am Acad Dermatol* 2006;54:1039–1045.
136. Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. *Arch Dermatol* 1999;135:1177–1183.
137. Chren MM, Torres JS, Stuart SE, et al. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. *Arch Dermatol* 2011;147:540–546.
138. Julian C, Bowers PW, Pritchard C. A comparative study of the effects of disposable and Volkmann spoon curettes in the treatment of basal cell carcinoma. *Br J Dermatol* 2009;161:1407–1409.
139. Blixt E, Nelsen D, Stratman E. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone. *Dermatol Surg* 2013;39:719–725.
140. Rodríguez-Vigil T, Vázquez-López F, Pérez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. *J Am Acad Dermatol* 2007;56:91–95.
141. Kopf AW, Bart RS, Schrager D, et al. Curettage-electrodesiccation treatment of basal cell carcinomas. *Arch Dermatol* 1977;113:439–443.
142. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. *J Dermatol Surg Oncol* 1989;15:424–431.
143. van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. *Eur J Cancer* 2014;50:3011–3020.
144. Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. *Plast Reconstr Surg* 1987;80:47–54.
145. Dando EE, Abban C, Shehu Wingrove A, et al. Deep shave removal of suspected basal cell carcinoma: a prospective study. *Dermatol Surg* 2023;49:130–134.
146. Abramson AK, Krasny MJ, Goldman GD. Tangential shave removal of basal cell carcinoma. *Dermatol Surg* 2013;39:387–392.
147. Wu X, Elkin EB, Jason Chen CS, et al. Traditional versus streamlined management of basal cell carcinoma (BCC): a cost analysis. *J Am Acad Dermatol* 2015;73:791–798.
148. Kuijpers DJ, Thissen MR, Berretty PJ, et al. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. *Dermatol Surg* 2007;33:579–587.
149. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. *Arch Dermatol* 2007;143:1131–1136.
150. Wetzig T, Woitek M, Eichhorn K, et al. Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up. *Dermatology* 2010;220:363–369.
151. Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. *JAMA Facial Plastic Surg* 2013;15:337–343.
152. Quazi SJ, Aslam N, Saleem H, et al. Surgical margin of excision in basal cell carcinoma: a systematic review of literature. *Cureus* 2020;12:e9211.
153. Bisson MA, Dunkin CS, Suvana SK, et al. Do plastic surgeons resect basal cell carcinomas too widely? A prospective study comparing surgical and histological margins. *Br J Plast Surg* 2002;55:293–297.
154. Gullette Y, Goldberg N, Silverman RP, et al. What is the best surgical margin for a basal cell carcinoma: a meta-analysis of the literature. *Plast Reconstr Surg* 2010;126:1222–1231.
155. Thomas DJ, King AR, Peat BG. Excision margins for nonmelanotic skin cancer. *Plast Reconstr Surg* 2003;112:57–63.
156. Fraga SD, Besaw RJ, Murad F, et al. Complete margin assessment versus sectional assessment in surgically excised high-risk keratinocyte carcinomas: a systematic review and meta-analysis. *Dermatol Surg* 2022;48:704–710.
157. Su SY, Giorlando F, Ek EW, et al. Incomplete excision of basal cell carcinoma: a prospective trial. *Plast Reconstr Surg* 2007;120:1240–1248.
158. Farhi D, Dupin N, Palangíe A, et al. Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. *Dermatol Surg* 2007;33:1207–1214.
159. Kappelin J, Nielsen K, Nilsson F, et al. Surgical treatment of basal cell carcinoma: a case series on factors influencing the risk of an incomplete primary excision. *J Eur Acad Dermatol Venereol* 2020;34:2518–2525.
160. Dieu T, Macleod AM. Incomplete excision of basal cell carcinomas: a retrospective audit. *ANZ J Surg* 2002;72:219–221.
161. Ramdas K, van Lee C, Beck S, et al. Differences in rate of complete excision of basal cell carcinoma by dermatologists, plastic surgeons and general practitioners: a large cross-sectional study. *Dermatology* 2018;234:86–91.
162. Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. *J Am Acad Dermatol* 1990;23:1118–1126.
163. Sherry KR, Reid LA, Wilmschurst AD. A five year review of basal cell carcinoma excisions. *J Plast Reconstr Aesthet Surg* 2010;63:1485–1489.
164. Griffiths RW, Suvana SK, Stone J. Basal cell carcinoma histological clearance margins: an analysis of 1539 conventionally excised tumours. Wider still and deeper? *J Plast Reconstr Aesthet Surg* 2007;60:41–47.
165. Masud D, Moustaki M, Staruch R, et al. Basal cell carcinoma: risk factors for incomplete excision and results of re-excision. *J Plast Reconstr Aesthet Surg* 2016;69:652–656.
166. Malik V, Goh KS, Leong S, et al. Risk and outcome analysis of 1832 consecutively excised basal cell carcinomas in a tertiary referral plastic surgery unit. *J Plast Reconstr Aesthet Surg* 2010;63:2057–2063.
167. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. *Arch Dermatol* 1987;123:340–344.
168. Weesie F, Naus NC, Vasilic D, et al. Recurrence of periocular basal cell carcinoma and squamous cell carcinoma after Mohs micrographic surgery: a retrospective cohort study. *Br J Dermatol* 2019;180:1176–1182.
169. Drucker AM, Adam GP, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. *Ann Intern Med* 2018;169:456–466.
170. Wennberg AM, Larkö O, Stenquist B. Five-year results of Mohs' micrographic surgery for aggressive facial basal cell carcinoma in Sweden. *Acta Derm Venereol* 1999;79:370–372.
171. Veronese F, Farinelli P, Zavattaro E, et al. Basal cell carcinoma of the head region: therapeutic results of 350 lesions treated with Mohs micrographic surgery. *J Eur Acad Dermatol Venereol* 2012;26:838–843.

172. Litwin AS, Rytina E, Ha T, et al. Management of periocular basal cell carcinoma by Mohs micrographic surgery. *J Dermatolog Treat* 2013;24:232–234.
173. Sin CW, Barua A, Cook A. Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study. *Int J Dermatol* 2016;55:1044–1047.
174. Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. *J Am Acad Dermatol* 2005;53:452–457.
175. Malhotra R, Huilgol SC, Huynh NT, et al. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. *Ophthalmology* 2004;111:631–636.
176. Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. *Lancet Oncol* 2008;9:1149–1156.
177. Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. *Lancet* 2004;364:1766–1772.
178. Muller FM, Dawe RS, Moseley H, et al. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. *Dermatol Surg* 2009;35:1349–1354.
179. Gniadecki R, Glud M, Mortensen K, et al. Favourable results of Mohs micrographic surgery for basal cell carcinoma. *Dan Med J* 2015;62:A5171.
180. Flohri SC, van Dorst AM, Nijsten T, et al. Mohs micrographic surgery for basal cell carcinomas: appropriateness of 'Rotterdam' criteria and predictive factors for three or more stages. *J Eur Acad Dermatol Venerol* 2013;27:1228–1235.
181. Takata Pontes L, Fantelli Stelini R, Cintra ML, et al. The importance of superficial basal cell carcinoma in a retrospective study of 139 patients who underwent Mohs micrographic surgery in a Brazilian university hospital. *Clinics (Sao Paulo)* 2015;70:721–725.
182. Morris DS, Elzaridi E, Clarke L, et al. Periocular basal cell carcinoma: 5-year outcome following Slow Mohs surgery with formalin-fixed paraffin-embedded sections and delayed closure. *Br J Ophthalmol* 2009;93:474–476.
183. Mendenhall WM, Amdur RJ, Hinerman RW, et al. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. *Laryngoscope* 2009;119:1994–1999.
184. Mendenhall WM, Ferlito A, Takes RP, et al. Cutaneous head and neck basal and squamous cell carcinomas with perineural invasion. *Oral Oncol* 2012;48:918–922.
185. Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? *Cancer* 2007;109:1053–1059.
186. Wilder RB, Kittelson JM, Shimm DS. Basal cell carcinoma treated with radiation therapy. *Cancer* 1991;68:2134–2137.
187. Wilder RB, Shimm DS, Kittelson JM, et al. Recurrent basal cell carcinoma treated with radiation therapy. *Arch Dermatol* 1991;127:1668–1672.
188. Childers BJ, Goldwyn RM, Ramos D, et al. Long-term results of irradiation for basal cell carcinoma of the skin of the nose. *Plast Reconstr Surg* 1994;93:1169–1173.
189. Hernández-Machin B, Borrego L, Gil-García M, et al. Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. *Int J Dermatol* 2007;46:453–459.
190. Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. *J Dermatol Surg Oncol* 1992;18:549–554.
191. Zagrodnik B, Kempf W, Seifert B, et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. *Cancer* 2003;98:2708–2714.
192. Cognetta AB, Howard BM, Heaton HP, et al. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. *J Am Acad Dermatol* 2012;67:1235–1241.
193. Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. *Br J Cancer* 1997;76:100–106.
194. Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. *Plast Reconstr Surg* 2000;105:2544–2551.
195. Hall VL, Leppard BJ, McGill J, et al. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. *Clin Radiol* 1986;37:33–34.
196. Garcia-Martin E, Gil-Arribas LM, Idoipe M, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. *Br J Ophthalmol* 2011;95:1393–1396.
197. Zaorsky NG, Lee CT, Zhang E, et al. Hypofractionated radiation therapy for basal and squamous cell skin cancer: a meta-analysis. *Radiother Oncol* 2017;125:13–20.
198. Ashby MA, Pacella JA, de Groot R, et al. Use of a radon mould technique for skin cancer: results from the Peter MacCallum Cancer Institute (1975–1984). *Br J Radiol* 1989;62:608–612.
199. Cipriani C, Desantis M, Dahlhoff G, et al. Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study. *J Dermatolog Treat* 2022;33:969–975.
200. Sedda AF, Rossi G, Cipriani C, et al. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. *Clin Exp Dermatol* 2008;33:745–749.
201. Guibert M, David I, Vergez S, et al. Brachytherapy in lip carcinoma: long-term results. *Int J Radiat Oncol Biol Phys* 2011;81:e839–e843.
202. Ballester-Sánchez R, Pons-Llanas O, Candela-Juan C, et al. Two years results of electronic brachytherapy for basal cell carcinoma. *J Contemp Brachytherapy* 2017;9:251–255.
203. Bhatnagar A, Loper A. The initial experience of electronic brachytherapy for the treatment of non-melanoma skin cancer. *Radiat Oncol* 2010;5:87.
204. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. *J Am Acad Dermatol* 2007;56:125–143.
205. Jansen MHE, Mosterd K, Arits AH, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. *J Invest Dermatol* 2018;138:527–533.
206. Drew BA, Karia PS, Mora AN, et al. Treatment patterns, outcomes, and patient satisfaction of primary epidermally limited nonmelanoma skin cancer. *Dermatol Surg* 2017;43:1423–1430.
207. Afsar FS, Erkan CD, Karaca S. Clinical practice trends in cryosurgery: a retrospective study of cutaneous lesions. *Postepy Dermatol Alergol* 2015;32:88–93.
208. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. *Dermatol Surg* 2005;31:318–323.
209. Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. *J Am Acad Dermatol* 2007;57:616–621.
210. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. *J Am Acad Dermatol* 2004;50:722–733.
211. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. *Br J Dermatol* 2005;152:939–947.
212. Quirk C, Gebauer K, De'Ambrosio B, et al. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. *Cutis* 2010;85:318–324.
213. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. *J Am Acad Dermatol* 2001;44:807–813.
214. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. *Eur J Dermatol* 2008;18:677–682.
215. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC. *Br J Dermatol* 2013;169:549–554.
216. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. *Lancet Oncol* 2014;15:96–105.
217. Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. *J Invest Dermatol* 2017;137:614–619.

218. Metterle L, Nelson C, Patel N. Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): a review. *J Am Acad Dermatol* 2016;74:552–557.
219. Neale H, Michelon M, Jacob S, et al. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: a retrospective cohort analysis. *J Am Acad Dermatol* 2022;87:423–425.
220. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single-blind, non-inferiority, randomised controlled trial. *Lancet Oncol* 2013;14:647–654.
221. Roozeboom MH, Arits AHMM, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. *J Invest Dermatol* 2016;136:1568–1574.
222. Gross K, Kirck L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. *Dermatol Surg* 2007;33:433–439; discussion 440.
223. Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. *Dermatologica* 1979;158:368–372.
224. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. *Arch Dermatol* 2009;145:1431–1438.
225. Kuijpers DI, Thissen MR, Thissen CA, et al. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. *J Drugs Dermatol* 2006;5:642–645.
226. Savoia P, Deboli T, Previgliano A, et al. Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma. *Int J Mol Sci* 2015;16:23300–23317.
227. Oseroff AR, Blumenson LR, Wilson BD, et al. A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. *Lasers Surg Med* 2006;38:417–426.
228. Berroeta L, Clark C, Dawe RS, et al. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. *Br J Dermatol* 2007;157:401–403.
229. Szeimies RM, Ibbotson SH, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. *J Eur Acad Dermatol Venereol* 2008;22:1302–1311.
230. Roozeboom MH, Aardoom MA, Nelemans PJ, et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. *J Am Acad Dermatol* 2013;69:280–287.
231. Cosgarea R, Susan M, Crisan M, et al. Photodynamic therapy using topical 5-aminolevulinic acid vs. surgery for basal cell carcinoma. *J Eur Acad Dermatol Venereol* 2013;27:980–984.
232. Wang H, Xu Y, Shi J, et al. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. *Photodermatol Photoimmunol Photomed* 2015;31:44–53.
233. Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. *Arch Dermatol* 2004;140:17–23.
234. Collier NJ, Haylett AK, Wong TH, et al. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis. *Br J Dermatol* 2018;179:1277–1296.
235. Zou Y, Zhao Y, Yu J, et al. Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. *J Cosmet Dermatol* 2016;15:374–382.
236. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. *Br J Dermatol* 2003;149:1242–1249.
237. Christensen E, Mørk C, Skogvoll E. High and sustained efficacy after two sessions of topical 5-aminolevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. *Br J Dermatol* 2012;166:1342–1348.
238. Zeitouni NC, Shieh S, Oseroff AR. Laser and photodynamic therapy in the management of cutaneous malignancies. *Clin Dermatol* 2001;19:328–338.
239. Osiecka B, Jarczyszyn K, Ziolkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. *Med Sci Monit* 2012;18:P15–P19.
240. Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. *Br J Dermatol* 2008;159:864–870.
241. Fantini F, Greco A, Del Giovane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. *J Eur Acad Dermatol Venereol* 2011;25:896–901.
242. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolevulinate for 'difficult-to-treat' basal cell carcinoma. *Br J Dermatol* 2005;152:765–772.
243. Sotiriou E, Apalla Z, Maliamani F, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. *J Eur Acad Dermatol Venereol* 2009;23:1061–1065.
244. Morton CA, McKenna KE, Rhodes LE, et al. Guidelines for topical photodynamic therapy: update. *Br J Dermatol* 2008;159:1245–1266.
245. Kokoszka A, Scheinfeld N. Evidence-based review of the use of cryosurgery in treatment of basal cell carcinoma. *Dermatol Surg* 2003;29:566–571.
246. Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. *J Am Acad Dermatol* 1991;24:1002–1004.
247. Mallon E, Dawber R. Cryosurgery in the treatment of basal cell carcinoma. Assessment of one and two freeze-thaw cycle schedules. *Dermatol Surg* 1996;22:854–858.
248. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. *Br J Dermatol* 2001;144:832–840.
249. Basset-Seguin N, Ibbotson SH, Erntestam L, et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. *Eur J Dermatol* 2008;18:547–553.
250. Thissen MR, Nieman FH, Ideler AH, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. *Dermatol Surg* 2000;26:759–764.
251. Roozeboom MH, Arits AHMM, Nelemans PJ, et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. *Br J Dermatol* 2012;167:733–756.
252. Roozeboom MH, Nelemans PJ, Mosterd K, et al. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial. *Br J Dermatol* 2015;172:739–745.
253. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. *N Engl J Med* 2015;373:1618–1626.
254. Chen AC, Martin AJ, Dalziel RA, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. *Br J Dermatol* 2016;175:1073–1075.
255. Surjana D, Halliday GM, Martin AJ, et al. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. *J Invest Dermatol* 2012;132:1497–1500.
256. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. *J Natl Cancer Inst* 2010;102:1835–1844.
257. Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). *Cancer* 2012;118:2128–2137.
258. Schauder DM, Kim J, Nijhawan RI. Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma: a systematic review. *JAMA Dermatol* 2020;156:1117–1124.
259. Tang JY, Chiou AS, Mackay-Wiggan JM, et al. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. *Cancer Prev Res (Phila)* 2014;7:292–299.
260. Prescribing information for vismodegib capsule for oral use. 2023. Accessed September 1, 2023. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/203388s0171bl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203388s0171bl.pdf)
261. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med* 2012;366:2171–2179.

262. Sekulic A, Migden MR, Lewis KD, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. *J Am Acad Dermatol* 2015;72:1021–1026.e8.
263. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. *BMC Cancer* 2017;17:332.
264. Dreno B, Basset-Seguin N, Caro I, et al. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. *Oncologist* 2014;19:790–796.
265. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. *N Engl J Med* 2012;366:2180–2188.
266. Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 2016;17:1720–1731.
267. Ally MS, Tang JY, Joseph T, et al. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome. *JAMA Dermatol* 2014;150:542–545.
268. Prescribing information for sonidegib capsules, for oral use. 2023. Accessed September 1, 2023. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/205266s009lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205266s009lbl.pdf)
269. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. *Lancet Oncol* 2015;16:716–728.
270. Lewis K, Dummer R, Farberg AS, et al. Effects of Sonidegib following dose reduction and treatment interruption in patients with advanced basal cell carcinoma during 42-month BOLT trial. *Dermatol Ther (Heidelb)* 2021;11:2225–2234.
271. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. *J Eur Acad Dermatol Venereol* 2018;32:372–381.
272. Dummer R, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. *Br J Dermatol* 2020;182:1369–1378.
273. Dummer R, Lear JT, Guminski A, et al. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: results from the final analysis of the randomized phase 2 basal cell carcinoma outcomes with LDE225 treatment (BOLT) trial at 42 months. *J Am Acad Dermatol* 2021;84:1162–1164.
274. Gutzmer R, Robert C, Loquai C, et al. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. *BMC Cancer* 2021;21:1244.
275. Danial C, Sarin KY, Oro AE, et al. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. *Clin Cancer Res* 2016;22:1325–1329.
276. Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. *J Am Acad Dermatol* 2014;71:904–911.e1.
277. Sofen H, Gross KG, Goldberg LH, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. *J Am Acad Dermatol* 2015;73:99–105.e1.
278. Tauber G, Pavlovsky L, Fenig E, et al. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. *J Am Acad Dermatol* 2015;73:799–801.
279. Bertrand N, Guerreschi P, Basset-Seguin N, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma. *EClinicalMedicine* 2021;35:100844.
280. Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. *Lancet Oncol* 2017;18:404–412.
281. Scalvenzi M, Cappello M, Costa C, et al. Low-dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: high efficacy with minimal toxicity. *Dermatol Ther (Heidelb)* 2020;10:465–468.
282. Jimeno A, Weiss GJ, Miller WH Jr, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. *Clin Cancer Res* 2013;19:2766–2774.
283. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. *J Clin Oncol* 2014;32:745–751.
284. Prescribing information for cemiplimab-rwlc injection, for intravenous use. 2020. Accessed September 1, 2023. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/761097s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761097s003lbl.pdf)
285. Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. *Lancet Oncol* 2021;22:848–857.
286. Carneiro BA, Watkin WG, Mehta UK, et al. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. *Cancer Invest* 2006;24:396–400.
287. Jefford M, Kiffer JD, Somers G, et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. *ANZ J Surg* 2004;74:704–705.
288. Ganti AK, Kessinger A. Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. *Cancer Treat Rev* 2011;37:440–443.
289. Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. *JAMA Dermatol* 2013;149:615–616.
290. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. *Eur J Cancer* 1990;26:73–77.
291. Moeholt K, Aagaard H, Pfeiffer P, et al. Platinum-based cytotoxic therapy in basal cell carcinoma—a review of the literature. *Acta Oncol* 1996;35:677–682.
292. Guthrie TH Jr, Porubsky ES, Luxenberg MN, et al. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. *J Clin Oncol* 1990;8:342–346.
293. Robinson JK. Follow-up and prevention (basal cell carcinoma). In: Miller SJ, Maloney ME, eds. *Cutaneous Oncology: Pathophysiology, Diagnosis, and Management*. Blackwell Science; 1998:pp. 695–698.
294. Marci I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. *Arch Dermatol* 2000;136:1524–1530.
295. Ramachandran S, Rajaratnam R, Smith AG, et al. Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. *J Am Acad Dermatol* 2009;61:247–251.
296. Flohil SC, van der Leest RJ, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. *Eur J Cancer* 2013;49:2365–2375.

| Individual Disclosures for the NCCN Basal Cell Skin Cancer Panel |                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                |                                                             |                                                                            |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|----------------------------------------------------------------------------|
| Panel Member                                                     | Clinical Research Support/Data Safety Monitoring Board                                                                                                                                                                                                                                                                                    | Scientific Advisory Boards, Consultant, or Expert Witness                                                                                      | Promotional Advisory Boards, Consultant, or Speakers Bureau | Specialization                                                             |
| Sumaira Z. Aasi, MD                                              | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Murad Alam, MD, MBA, MSCI                                        | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology; Surgery/Surgical oncology; Otolaryngology                     |
| Arya Amini, MD                                                   | Regeneron Pharmaceuticals; Varian Medical Systems, Inc.                                                                                                                                                                                                                                                                                   | AstraZeneca Pharmaceuticals LP                                                                                                                 | None                                                        | Radiotherapy/Radiation oncology                                            |
| Kristin Bibee, MD, PhD                                           | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Rachel Blitzblau, MD, PhD                                        | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Radiation oncology                                                         |
| Jeremy Bordeaux, MD, MPH                                         | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Pei-Ling Chen, MD, PhD                                           | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Pathology/<br>Dermatopathology                                             |
| Carlo M. Contreras, MD                                           | The Ohio State University Innovation Studio; The Ohio State University Intramural Research Program                                                                                                                                                                                                                                        | None                                                                                                                                           | None                                                        | Surgery/Surgical oncology                                                  |
| Dominick DiMaio, MD                                              | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Pathology/<br>Dermatopathology                                             |
| Jessica M. Donigan, MD                                           | Castle Biosciences                                                                                                                                                                                                                                                                                                                        | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Jeffrey M. Farma, MD                                             | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Surgery/Surgical oncology                                                  |
| Karthik Ghosh, MD                                                | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Internal medicine                                                          |
| Kelly Harms, MD, PhD                                             | OncoSec                                                                                                                                                                                                                                                                                                                                   | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Alan L. Ho, MD, PhD <sup>a</sup>                                 | Affymune; Astellas Pharma US, Inc.; AstraZeneca Pharmaceuticals LP; Ayala Pharmaceuticals; Bayer HealthCare; Bioatla; Bristol Myers Squibb; Eisai Inc.; Elevar; Genentech, Inc.; GSK; Hookipa; Kura Oncology, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncC4; Poseida Therapeutics; Regeneron Pharmaceuticals, Inc. | Eisai Inc.; Elevar Therapeutics; Exelixis Inc.; ExpertConnect; Kura Oncology, Inc.; Merck & Co., Inc.; Remix Therapeutics; Rgenta Therapeutics | Physician Education Resource                                | Medical oncology                                                           |
| John Nicholas Lukens, MD                                         | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Radiotherapy/Radiation oncology                                            |
| Lawrence Mark, MD, PhD                                           | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Theresa Medina, MD                                               | Agenus; Anaveon; Bioatla, Inc; Bristol Myers Squibb; Day One; Genentech, Inc.; Infla-Rx; Iovance pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals; Replimune; SeaGen; Ultimovacs                                                                                                                                | None                                                                                                                                           | None                                                        | Medical oncology                                                           |
| Kishwer S. Nehal, MD                                             | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Paul Nghiem, MD, PhD                                             | None                                                                                                                                                                                                                                                                                                                                      | Almirall                                                                                                                                       | None                                                        | Dermatology                                                                |
| Kelly Olino, MD                                                  | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Surgery/Surgical oncology                                                  |
| Soo Park, MD                                                     | Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.                                                                                                                                                                                                                                                                                        | Regeneron Pharmaceuticals, Inc.                                                                                                                | None                                                        | Medical oncology                                                           |
| Tejesh Patel, MD                                                 | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Igor Puzanov, MD, MSCI <sup>a</sup>                              | None                                                                                                                                                                                                                                                                                                                                      | Iovance Pharmaceuticals                                                                                                                        | None                                                        | Hematology/Hematologic oncology                                            |
| Jason Rich, MD                                                   | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Otolaryngology                                                             |
| Chrysalyn D. Schmults, MD, MS                                    | Castle Bioscience; Genentech, Inc.; InflaRX; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S.                                                                                                                                                                                | Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S.; SCOUT                                                                                    | None                                                        | Dermatology; Pathology/<br>Dermatopathology; Surgery/<br>Surgical oncology |
| Aleksandar Sekulic, MD, PhD                                      | Regeneron Pharmaceuticals, Inc.; Replimune                                                                                                                                                                                                                                                                                                | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Ashok R. Shaha, MD                                               | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Surgery/Surgical oncology                                                  |
| Divya Srivastava, MD                                             | Regeneron Pharmaceuticals, Inc.                                                                                                                                                                                                                                                                                                           | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Valencia Thomas, MD                                              | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Courtney Tomblinson, MD                                          | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Diagnostic/Interventional radiology                                        |
| Puja Venkat, MD                                                  | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Radiotherapy/Radiation oncology                                            |
| Yaohui Gloria Xu, MD, PhD                                        | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology; Reconstructive surgery                                        |
| Siegrid Yu, MD                                                   | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Dermatology                                                                |
| Mehran Yusuf, MD                                                 | None                                                                                                                                                                                                                                                                                                                                      | None                                                                                                                                           | None                                                        | Radiotherapy/Radiation oncology                                            |

The NCCN Guidelines Staff have no conflicts to disclose.

<sup>a</sup>The following individuals have disclosures relating to employment/governing board, patent, equity, or royalty:

Alan L. Ho, MD, PhD: International Thyroid Oncology Group; and Rgenta Therapeutics.

Igor Puzanov, MD, MSCI: IDEAYA Biosciences.